2024

Cost analysis of patients undergoing allogeneic stem cell transplantation or chimeric antigen receptor T-cell therapy in relapsed or refractory diffuse large B-cell lymphoma from a German healthcare payer perspective
Ahmadi P, Ghandili S, Jakobs F, Konnopka C, Morgner-Miehlke A, Kröger N, Ayuk F
BONE MARROW TRANSPL. 2024;59(4):572-574.

Flares of acute graft-versus-host disease: a Mount Sinai Acute GVHD International Consortium analysis
Akahoshi Y, Spyrou N, Hoepting M, Aguayo-Hiraldo P, Ayuk F, Chanswangphuwana C, Choe H, Eder M, Etra A, Grupp S, Hexner E, Hogan W, Kitko C, Kraus S, Al Malki M, Merli P, Qayed M, Reshef R, Schechter T, Ullrich E, Vasova I, Wölfl M, Zeiser R, Baez J, Beheshti R, Eng G, Gleich S, Kasikis S, Katsivelos N, Kowalyk S, Morales G, Young R, DeFilipp Z, Ferrara J, Levine J, Nakamura R
BLOOD ADV. 2024;8(8):2047-2057.

Novel MAGIC composite scores using both clinical symptoms and biomarkers best predict treatment outcomes of acute GVHD
Akahoshi Y, Spyrou N, Weber D, Aguayo-Hiraldo P, Ayuk F, Chanswangphuwana C, Choe H, Eder M, Etra A, Grupp S, Hexner E, Hogan W, Kitko C, Kraus S, Al Malki M, Merli P, Qayed M, Reshef R, Schechter T, Ullrich E, Vasova I, Wölfl M, Zeiser R, Baez J, Beheshti R, Eng G, Gleich S, Katsivelos N, Kowalyk S, Morales G, Young R, Chen Y, Nakamura R, Levine J, Ferrara J
BLOOD. 2024;144(9):1010-1021.

CARs come to AID
Ayuk F, Fehse B
MOL THER. 2024;32(4):861-862.

Treatment of newly diagnosed moderate or severe chronic graft-versus-host disease with prednisone and everolimus (PredEver first): a prospective multicenter phase IIA study
Ayuk F, Wagner-Drouet E, Wolff D, von Huenerbein N, von Pein U, Klyuchnikov E, von Harsdorf S, Koenecke C, Sayer H, Kröger N
BONE MARROW TRANSPL. 2024;59(8):1092-1096.

Does size matter?: Center-specific characteristics and survival after allogeneic hematopoietic cell transplantation for acute myeloid leukemia: an analysis of the German Registry for Stem Cell Transplantation and Cell Therapy
Bethge W, Flossdorf S, Hanke F, Schmid C, Ringhoffer M, Klein S, Hertenstein B, Schetelig J, Stelljes M, Schroeder T, Blau I, Ayuk F, Eder M, Zeiser R, Fleischhauer K, Kröger N, Dreger P
HAEMATOLOGICA. 2024 [Epub ahead of print].

Correction: Real‑world data suggest effectiveness of the allogeneic mesenchymal stromal cells preparation MSC‑FFM in ruxolitinib‑refractory acute graft‑versus‑host disease
Bonig H, Verbeek M, Herhaus P, Braitsch K, Beutel G, Schmid C, Müller N, Bug G, Döring M, von Stackelberg A, Tischer J, Ayuk F, Wulf G, Holtick U, Pfeffermann L, Jahrsdörfer B, Schrezenmeier H, Kuci S, Kuci Z, Zens A, Tribanek M, Zeiser R, Huenecke S, Bader P
J TRANSL MED. 2024;22(1):.

The MAGIC algorithm probability predicts treatment response and long-term outcomes to second-line therapy for acute GVHD
DeFilipp Z, Kim H, Spyrou N, Katsivelos N, Kowalyk S, Eng G, Kasikis S, Beheshti R, Baez J, Akahoshi Y, Ayuk F, Choe H, Etra A, Grupp S, Hexner E, Hogan W, Kitko C, Qayed M, Reshef R, Vasova I, Zeiser R, Young R, Holler E, Ferrara J, Nakamura R, Levine J, Chen Y
BLOOD ADV. 2024;8(13):3488-3496.

Amphiregulin, ST2, and REG3α biomarker risk algorithms as predictors of nonrelapse mortality in patients with acute GVHD
Etra A, El Jurdi N, Katsivelos N, Kwon D, Gergoudis S, Morales G, Spyrou N, Kowalyk S, Aguayo-Hiraldo P, Akahoshi Y, Ayuk F, Baez J, Betts B, Chanswangphuwana C, Chen Y, Choe H, DeFilipp Z, Gleich S, Hexner E, Hogan W, Holler E, Kitko C, Kraus S, Al Malki M, MacMillan M, Pawarode A, Quagliarella F, Qayed M, Reshef R, Schechter T, Vasova I, Weisdorf D, Wölfl M, Young R, Nakamura R, Ferrara J, Levine J, Holtan S
BLOOD ADV. 2024;8(12):3284-3292.

Long term results of a prospective multicenter observational study on the use of anti-human T-lymphocyte immunoglobulin (ATLG) in unrelated donor transplantation (ATOS study)
Finke J, Schmoor C, Ayuk F, Hasenkamp J, Verbeek M, Wagner E, Biersack H, Schäfer-Eckart K, Wolf D, Stuhler G, Reibke R, Schmid C, Kaufmann M, Eder M, Bertz H, Grishina O
BONE MARROW TRANSPL. 2024;59(7):936-941.

CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis
Fischbach F, Richter J, Pfeffer L, Fehse B, Berger S, Reinhardt S, Kuhle J, Badbaran A, Rathje K, Gagelmann N, Borie D, Seibel J, Ayuk F, Friese M, Heesen C, Kröger N
MED-CAMBRIDGE. 2024;5(6):550-558.e2.

Axicabtagene ciloleucel versus tisagenlecleucel for relapsed or refractory large B-cell lymphoma: a systematic review and meta-analysis
Gagelmann N, Bishop M, Ayuk F, Bethge W, Glass B, Sureda A, Pasquini M, Kröger N
TRANSPL CELL THER. 2024;30(6):584.e1-584.e13.

Development and Validation of a Prediction Model of Outcome After B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Multiple Myeloma
Gagelmann N, Dima D, Merz M, Hashmi H, Ahmed N, Tovar N, Oliver-Caldés A, Stölzel F, Rathje K, Fischer L, Born P, Schäfer L, Albici A, Schub N, Kfir-Erenfeld S, Assayag M, Asherie N, Wulf G, Kharboutli S, Müller F, Shune L, Davis J, Anwer F, Vucinic V, Platzbecker U, Ayuk F, Kröger N, Khouri J, Gurnari C, McGuirk J, Stepensky P, Abdallah A, Fernández de Larrea C
J CLIN ONCOL. 2024;42(14):1665-1675.

Successful treatment of refractory checkpoint inhibitor-induced hepatitis with quadruple therapy including extracorporeal photopheresis and infliximab
Hansen I, Kött J, Heidenreich S, Ayuk F, Doll P, Abeck F, Booken N, Gebhardt C, Schneider S
Journal of the European Academy of Dermatology and Venerology Clinical Practice. 2024;3(1):317-320.

CD45-Directed CAR-T Cells with CD45 Knockout Efficiently Kill Myeloid Leukemia and Lymphoma Cells In Vitro Even after Extended Culture
Harfmann M, Schröder T, Głów D, Jung M, Uhde A, Kröger N, Horn S, Riecken K, Fehse B, Ayuk F
CANCERS. 2024;16(2):.

Real-World Outcomes with Chimeric Antigen Receptor T Cell Therapies in Large B Cell Lymphoma: A Systematic Review and Meta-Analysis
Jacobson C, Munoz J, Sun F, Kanters S, Limbrick-Oldfield E, Spooner C, Mignone K, Ayuk F, Sanderson R, Whitmore J, Wang Y, Xu H, Dickinson M
TRANSPL CELL THER. 2024;30(1):77.e1-77.e15.

Serial Clinical and Biomarker Monitoring during Graft-Versus-Host Disease Treatment Identifies Distinct Risk Strata Including an Ultra-Low Risk Group
Katsivelos N, Spyrou N, Weber D, Vasova I, Ayuk F, Choe H, Hogan W, DeFilipp Z, Qayed M, Etra A, Sandhu K, Kraus S, Olson T, Hexner E, Aguayo-Hiraldo P, Reshef R, Ullrich E, Schechter T, Kitko C, Chanswangphuwana C, Merli P, Akahoshi Y, Baez J, Eng G, Beheshti R, Kowalyk S, Morales G, Louloudis I, Young R, Holler E, Nakamura R, Ferrara J, Levine J
TRANSPL CELL THER. 2024 [Epub ahead of print].

Peri-transplant flow-MRD assessment of cells with leukemic stem cells (LSC) associated phenotype in AML patients undergoing allogeneic stem cell transplantation in CR
Klyuchnikov E, Badbaran A, Massoud R, Freiberger P, Wolschke C, Ayuk F, Fehse B, Bacher U, Kröger N
LEUKEMIA. 2024;38(2):386-388.

Autologous-allogeneic versus autologous tandem stem cell transplantation and maintenance therapy with thalidomide for multiple myeloma patients under 60 years of age: a prospective phase II study
Kröger N, Wulf G, Hegenbart U, Burchert A, Stelljes M, Gagelmann N, Brecht A, Kaufmann M, Müller L, Ganser A, Wolf D, Bethge W, Bornhäuser M, Kiehl M, Wagner E, Schmid C, Reinhardt H, Kobbe G, Salwender H, Heinicke T, Kropff M, Heinzelmann M, Ayuk F, Trümper L, Neubauer A, Völp A, Kluychnikov E, Schönland S, Wolschke C
HAEMATOLOGICA. 2024;109(5):1469-1479.

Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis: A retrospective analysis of the DRST and GREM registries
Lübke J, Christen D, Schwaab J, Kaiser A, Naumann N, Shoumariyeh K, Jentzsch M, Sockel K, Schaffrath J, Ayuk F, Stelljes M, Hilgendorf I, Sala E, Kaivers J, Schönland S, Wittke C, Hertenstein B, Radsak M, Kaiser U, Brückl V, Kröger N, Brümmendorf T, Hofmann W, Klein S, Jost E, Reiter A, Panse J
LEUKEMIA. 2024;38(4):810-821.

Sequential Conditioning With FLAMSA Does Not Improve Outcomes of Allogeneic Stem Cell Transplantation in Chronic Myelomonocytic Leukemia Patients
Massoud R, Klyuchnikov E, Steiner N, Zeck G, Heidenreich S, Langebrake C, Niederwieser C, Rathje K, Gagelmann N, Janson D, Wolschke C, Ayuk F, Kröger N
TRANSPL CELL THER. 2024 [Epub ahead of print].

Allogeneic hematopoetic stem cell transplant for patients with refractory T-Cell lymphomas
Massoud R, Naim H, Klyuchnikov E, Janson D, Wolschke C, Ayuk F, Kröger N
EUR J HAEMATOL. 2024;112(2):276-285.

Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy
Merz M, Dima D, Hashmi H, Ahmed N, Stölzel F, Holderried T, Fenk R, Müller F, Tovar N, Oliver-Cáldes A, Rathje K, Davis J, Fandrei D, Vucinic V, Kharboutli S, Baermann B, Ayuk F, Platzbecker U, Albici A, Schub N, Schmitz F, Shune L, Khouri J, Anwer F, Raza S, McGuirk J, Mahmoudjafari Z, Green K, Khandanpour C, Teichert M, Jeker B, Hoffmann M, Kröger N, von Tresckow B, de Larrea C, Pabst T, Abdallah A, Gagelmann N
BLOOD CANCER J. 2024;14(1):214.

Graft-versus-host disease and impact on relapse in myelofibrosis undergoing hematopoietic stem cell transplantation
Oechsler S, Gagelmann N, Wolschke C, Janson D, Badbaran A, Klyuchnikov E, Massoud R, Rathje K, Richter J, Schäfersküpper M, Niederwieser C, Kunte A, Heidenreich S, Ayuk F, Kröger N
BONE MARROW TRANSPL. 2024;59(4):550-557.

Management of Patients Undergoing CAR-T Cell Therapy in Germany
Penack O, Dreger P, Ajib S, Ayuk F, Baermann B, Bug G, Kriege O, Jentzsch M, Kobbe G, Koenecke C, Lutz M, Martin S, Schlegel P, Schroers R, von Tresckow B, Vucinic V, Subklewe M, Bethge W, Wolff D
ONCOL RES TREAT. 2024;47(3):65-75.

A Validated Risk Stratification That Incorporates MAGIC Biomarkers Predicts Long-Term Outcomes in Pediatric Patients with Acute GVHD
Qayed M, Kapoor U, Gillespie S, Westbrook A, Aguayo-Hiraldo P, Ayuk F, Aziz M, Baez J, Choe H, DeFilipp Z, Etra A, Grupp S, Hexner E, Holler E, Hogan W, Kowalyk S, Merli P, Morales G, Nakamura R, Pulsipher M, Schechter T, Shah J, Spyrou N, Srinagesh H, Wölfl M, Yanik G, Young R, Kitko C, Ferrara J, Levine J
TRANSPL CELL THER. 2024;30(6):603.e1-603.e11.

Clinical and Immune Effects of Peri-Transplantation JAK Inhibition for Myelofibrosis
Rathje K, Gagelmann N, Badbaran A, Langebrake C, Dadkhah A, Richter J, Massoud R, Schäfersküpper M, Marquard F, Oechsler S, Klyuchnikov E, Rudolph I, Heidenreich S, Niederwieser C, Lueck C, Janson D, Wolschke C, Fehse B, Ayuk F, Kröger N
AM J HEMATOL. 2024 [Epub ahead of print].

Differences in Acute Graft-Versus-Host Disease (GVHD) Severity and Its Outcomes Between Black and White Patients
Rios C, Qayed M, Etra A, Reshef R, Newcomb R, Yuhasz N, Hexner E, Aguayo-Hiraldo P, Merli P, Hogan W, Weber D, Kitko C, Ayuk F, Eder M, Grupp S, Kraus S, Sandhu K, Ullrich E, Vasova I, Wölfl M, Baez J, Beheshti R, Eng G, Gleich S, Katsivelos N, Kowalyk S, Louloudis I, Morales G, Spyrou N, Young R, Nakamura R, Levine J, Ferrara J, Akahoshi Y
TRANSPL CELL THER. 2024;30(11):1061.e1-1061.e10.

Dose-Reduced FLA-IDA in Combination with Venetoclax Is an Effective and Safe Salvage Therapy in Relapsed and Refractory Acute Myeloid Leukemia (R/R AML)
Schönrock M, Sonnemann P, Michalowski N, Heuser M, Thol F, Ayuk F, Wolschke C, Klyuchnikov E, Bokemeyer C, Fiedler W, Cichutek S
CANCERS. 2024.

Dose-Reduced FLA-IDA in Combination with Venetoclax Is an Effective and Safe Salvage Therapy in Relapsed and Refractory Acute Myeloid Leukemia (R/R AML)
Schönrock M, Sonnemann P, Michalowski N, Heuser M, Thol F, Ayuk F, Wolschke C, Klyuchnikov E, Bokemeyer C, Fiedler W, Cichutek S
CANCERS. 2024;16(22):.

Hope for motherhood: pregnancy after allogeneic hematopoietic cell transplantation (a national multicenter study)
Sockel K, Neu A, Goeckenjan M, Ditschkowski M, Hilgendorf I, Kröger N, Ayuk F, Stoelzel F, Middeke J, Eder M, Bethge W, Finke J, Bertz H, Kobbe G, Kaufmann M, Platzbecker U, Beverungen D, Schmid C, von Bonin M, Egger-Heidrich K, Heberling L, Trautmann-Grill K, Teipel R, Bug G, Tischer J, Fraccaroli A, Fante M, Wolff D, Luft T, Winkler J, Schäfer-Eckart K, Scheid C, Holtick U, Klein S, Blau I, Burchert A, Wulf G, Hasenkamp J, Schwerdtfeger R, Kaun S, Junghanss C, Wortmann F, Winter S, Neidlinger H, Theuser C, Beyersmann J, Bornhaeuser M, Schmeller S, Schetelig J
BLOOD. 2024;144(14):1532-1542.

A Day 14 Endpoint for Acute GVHD Clinical Trials
Spyrou N, Akahoshi Y, Kowalyk S, Morales G, Beheshti R, Aguayo-Hiraldo P, Al Malki M, Ayuk F, Bader P, Baez J, Capellini A, Choe H, DeFilipp Z, Eder M, Eng G, Etra A, Gleich S, Grupp S, Hexner E, Hoepting M, Hogan W, Kasikis S, Katsivelos N, Khan A, Kitko C, Kraus S, Kwon D, Merli P, Portelli J, Qayed M, Reshef R, Schechter T, Vasova I, Wölfl M, Wudhikarn K, Young R, Holler E, Chen Y, Nakamura R, Levine J, Ferrara J
TRANSPL CELL THER. 2024;30(4):421-432.

Anti-T-lymphocyte globulin (ATLG) compared to post-transplant cyclophosphamide as GvHD prophylaxis in ALL patients undergoing allogeneic stem cell transplantation
Steiner N, Massoud R, Klyuchnikov E, Gagelmann N, Richter J, Niederwieser C, Rathje K, Urbanowicz T, Kunte A, Engelmann J, Ihne C, Lastovytska I, Lindhauer C, Marquard F, Reichard M, Ryzhkova A, Sabauri R, Schäfersküpper M, Seyedi N, Kalogeropoulos G, Heidenreich S, Rudolph I, Zeck G, Janson D, Wolschke C, Ayuk F, Kröger N
BONE MARROW TRANSPL. 2024;59(9):1265-1274.

Development and Validation of a Concise Objectifiable Risk Evaluation Score for Non-Relapse Mortality after Allogeneic Hematopoietic Stem Cell Transplantation
Weise G, Massoud R, Krause R, Heidenreich S, Janson D, Klyuchnikov E, Wolschke C, Zeck G, Kröger N, Ayuk F
CANCERS. 2024;16(3):.

Chimeric antigen receptor T-cell therapy and fludarabine precision dosing imperatives
Wicha S, Wansing E, Dadkhah A, Ayuk F, Kröger N, Langebrake C
BLOOD ADV. 2024;8(3):797-798.

2023

Impact of age on outcome of CAR-T cell therapies for large B-cell lymphoma: the GLA/DRST experience

BONE MARROW TRANSPL. 2023;58(2):229-232.

Incidence, clinical presentation, risk factors, outcomes, and biomarkers in de novo late acute GVHD
Akahoshi Y, Spyrou N, Hogan W, Ayuk F, DeFilipp Z, Weber D, Choe H, Hexner E, Rösler W, Etra A, Sandhu K, Yanik G, Chanswangphuwana C, Kitko C, Reshef R, Kraus S, Wölfl M, Eder M, Bertrand H, Qayed M, Merli P, Grupp S, Aguayo-Hiraldo P, Schechter T, Ullrich E, Baez J, Beheshti R, Gleich S, Kowalyk S, Morales G, Young R, Kwon D, Nakamura R, Levine J, Ferrara J, Chen Y
BLOOD ADV. 2023;7(16):4479-4491.

Phase 2 study of natalizumab plus standard corticosteroid treatment for high-risk acute graft-versus-host disease
Al Malki M, London K, Baez J, Akahoshi Y, Hogan W, Etra A, Choe H, Hexner E, Langston A, Abhyankar S, Ponce D, DeFilipp Z, Kitko C, Adekola K, Reshef R, Ayuk F, Capellini A, Chanswangphuwana C, Eder M, Eng G, Gandhi I, Grupp S, Gleich S, Holler E, Javorniczky N, Kasikis S, Kowalyk S, Morales G, Özbek U, Rösler W, Spyrou N, Yanik G, Young R, Chen Y, Nakamura R, Ferrara J, Levine J
BLOOD ADV. 2023;7(17):5189-5198.

Real-world results of CAR T-cell therapy for large B-cell lymphoma with CNS involvement: a GLA/DRST study
Ayuk F, Gagelmann N, von Tresckow B, Wulf G, Rejeski K, Stelljes M, Penack O, Baldus C, Kröger N, Bethge W, Dreger P
BLOOD ADV. 2023;7(18):5316-5319.

CD19 CAR T cells are an effective therapy for posttransplant relapse in patients with B-lineage ALL: Real-World Data from Germany
Bader P, Rossig C, Hutter M, Ayuk F, Baldus C, Bücklein V, Bonig H, Cario G, Einsele H, Holtick U, Koenecke C, Bakhtiar S, Künkele A, Meisel R, Mueller F, Müller I, Penack O, Rettinger E, Sauer M, Schlegel P, Soerensen J, von Stackelberg A, Strahm B, Feuchtinger T, Hauer J, Jarisch A
BLOOD ADV. 2023;7(11):2436-2448.

Data-driven grading of acute graft-versus-host disease
Bayraktar E, Graf T, Ayuk F, Beutel G, Penack O, Luft T, Brueder N, Castellani G, Reinhardt H, Kröger N, Beelen D, Turki A
NAT COMMUN. 2023;14(1):7799.

Molecular monitoring of T-cell kinetics and migration in severe neurotoxicity after real-world CD19-specific chimeric antigen receptor-T cell therapy
Berger S, Fehse B, Akyüz N, Geffken M, Wolschke C, Janson D, Gagelmann N, Luther M, Wichmann D, Frenzel C, Thayssen G, Alegiani A, Badbaran A, Zeschke S, Dierlamm J, Kröger N, Ayuk F
HAEMATOLOGICA. 2023;108(2):444-456.

Real-world data suggest effectiveness of the allogeneic mesenchymal stromal cells preparation MSC-FFM in ruxolitinib-refractory acute graft-versus-host disease
Bonig H, Verbeek M, Herhaus P, Braitssch K, Beutel G, Schmid C, Müller N, Bug G, Döring M, von Stackelberg A, Tischer J, Ayuk F, Wulf G, Holtick U, Pfeffermann L, Jahrsdörfer B, Schrezenmeier H, Kuci S, Kuci Z, Zens A, Tribanek M, Zeiser R, Huenecke S, Bader P
J TRANSL MED. 2023;21(1):837.

Long-Term Survivors after Failure of Chimeric Antigen Receptor T Cell Therapy for Large B Cell Lymphoma: A Role for Allogeneic Hematopoietic Cell Transplantation? A German Lymphoma Alliance and German Registry for Stem Cell Transplantation Analysis
Derigs P, Bethge W, Krämer I, Holtick U, von Tresckow B, Ayuk F, Penack O, Vucinic V, von Bonin M, Baldus C, Mougiakakos D, Wulf G, Schnetzke U, Stelljes M, Fante M, Schroers R, Kroeger N, Dreger P
TRANSPL CELL THER. 2023;29(12):750-756.

Iron Chelation with Deferasirox Suppresses the Appearance of Labile Plasma Iron During Conditioning Chemotherapy Prior to Allogeneic Stem Cell Transplantation
Essmann S, Heestermans M, Dadkhah A, Janson D, Wolschke C, Ayuk F, Kröger N, Langebrake C
TRANSPL CELL THER. 2023;29(1):42.e1-42.e6.

Effective treatment of low risk acute GVHD with itacitinib monotherapy
Etra A, Capellini A, Alousi A, Al Malki M, Choe H, DeFilipp Z, Hogan W, Kitko C, Ayuk F, Baez J, Gandhi I, Kasikis S, Gleich S, Hexner E, Hoepting M, Kapoor U, Kowalyk S, Kwon D, Langston A, Mielcarek M, Morales G, Özbek U, Qayed M, Reshef R, Roesler W, Spyrou N, Young R, Chen Y, Ferrara J, Levine J
BLOOD. 2023;141(5):481-489.

Impact of high-risk disease on the efficacy of chimeric antigen receptor T-cell therapy for multiple myeloma: a meta-analysis of 723 patients
Gagelmann N, Ayuk F, Klyuchnikov E, Wolschke C, Berger S, Kröger N
HAEMATOLOGICA. 2023;108(10):2799-2802.

Donor Lymphocyte Infusion and Molecular Monitoring for Relapsed Myelofibrosis After Hematopoietic Cell Transplantation
Gagelmann N, Wolschke C, Badbaran A, Janson D, Berger C, Klyuchnikov E, Ayuk F, Fehse B, Kröger N
HEMASPHERE. 2023;7(7):e921.

Hematopoietic stem cell boost for persistent neutropenia after CAR-T cell therapy: a GLA/DRST study
Gagelmann N, Wulf G, Duell J, Glass B, Heteren P, von Tresckow B, Fischer M, Penack O, Ayuk F, Einsele H, Holtick U, Thomson J, Dreger P, Kröger N
BLOOD ADV. 2023;7(4):555-559.

Prevention of CMV/EBV reactivation by double-specific T cells in patients after allogeneic stem cell transplantation: results from the randomized phase I/IIa MULTIVIR-01 study
Gerbitz A, Gary R, Aigner M, Moosmann A, Kremer A, Schmid C, Hirschbuehl K, Wagner E, Hauptrock B, Teschner D, Roesler W, Spriewald B, Tischer J, Moi S, Balzer H, Schaffer S, Bausenwein J, Wagner A, Schmidt F, Brestrich J, Ullrich B, Maas S, Herold S, Strobel J, Zimmermann R, Weisbach V, Hansmann L, Lammoglia-Cobo F, Remberger M, Stelljes M, Ayuk F, Zeiser R, Mackensen A
FRONT IMMUNOL. 2023;14:1251593.

Individualized busulfan dosing improves outcomes compared to fixed-dose administration in pre-transplant minimal residual disease-positive acute myeloid leukemia patients with intermediate-risk undergoing allogeneic stem cell transplantation in CR
Klyuchnikov E, Langebrake C, Badbaran A, Dadkhah A, Massoud R, Freiberger P, Ayuk F, Janson D, Wolschke C, Bacher U, Kröger N
EUR J HAEMATOL. 2023;110(2):188-197.

Spleen volume and length determined by computed tomography impact outcome after allogeneic stem cell transplantation for myelofibrosis
Luther M, Henes F, Zabelina T, Massoud R, Janson D, Wolschke C, Klyuchnikov E, Gagelmann N, Fehse B, Adam G, Kröger N, Ayuk F
BONE MARROW TRANSPL. 2023;58(7):755-761.

Case Report: Lymphodepletion followed by CAR-T cell therapy with Idecabtagen vicleucel in a patient with severe renal impairment
Marquard F, Langebrake C, Janson D, Mahmud M, Dadkhah A, Kröger N, Ayuk F
FRONT ONCOL. 2023;13:1288764.

Clinical Implications and Dynamics of Clonal Hematopoiesis in Anti-CD19 CAR T-cell Treated Patients
Panagiota V, Kerschbaum J, Penack O, Stein C, Arends C, Koenecke C, Strzelecka P, Kloos A, Wiegand L, Lasch A, Altwasser R, Halik A, Gabdoulline R, Thomson J, Weibl K, Franke G, Berger C, Hasenkamp J, Ayuk F, Na I, Beutel G, Keller U, Bullinger L, Wulf G, Kröger N, Vucinic V, Heuser M, Damm F
HEMASPHERE. 2023;7(10):e957.

Benchmarking of survival outcomes following Haematopoietic Stem Cell Transplantation (HSCT): an update of the ongoing project of the European Society for Blood and Marrow Transplantation (EBMT) and Joint Accreditation Committee of ISCT and EBMT (JACIE)
Saccardi R, Putter H, Eikema D, Busto M, McGrath E, Middelkoop B, Adams G, Atlija M, Ayuk F, Baldomero H, Beguin Y, de la Cámara R, Cedillo Á, Balari A, Chabannon C, Corbacioglu S, Dolstra H, Duarte R, Dulery R, Greco R, Gusi A, Hamad N, Kenyon M, Kröger N, Labopin M, Lee J, Ljungman P, Manson L, Mensil F, Milpied N, Mohty M, Oldani E, Orchard K, Passweg J, Pearce R, de Latour R, Poirel H, Rintala T, Rizzo J, Ruggeri A, Sanchez-Martinez C, Sanchez-Guijo F, Sánchez-Ortega I, Trnková M, Ferreiras D, Wilcox L, de Wreede L, Snowden J
BONE MARROW TRANSPL. 2023;58(6):659-666.

Outcomes of axicabtagene ciloleucel in PMBCL compare favorably with those in DLBCL: a GLA/DRST registry study
Schubert M, Bethge W, Ayuk F, von Bonin M, Vucinic V, Wagner-Drouet E, Subklewe M, Baldus C, Glass B, Marks R, Mougiakakos D, Schroers R, Stelljes M, Topp M, Wulf G, Kröger N, Dreger P
BLOOD ADV. 2023;7(20):6191-6195.

The utility of biomarkers in acute GVHD prognostication
Spyrou N, Akahoshi Y, Ayuk F, Holler E, Choe H, Etra A, Hogan W, Rösler W, Hexner E, DeFilipp Z, Reshef R, Chanswangphuwana C, Qayed M, Kraus S, Eder M, Javorniczky N, Grupp S, Kitko C, Merli P, Aguayo-Hiraldo P, Wölfl M, Baez J, Beheshti R, Eng G, Gleich S, Katsivelos N, Khan A, Kowalyk S, Morales G, Young R, Nakamura R, Chen Y, Levine J, Ferrara J
BLOOD ADV. 2023;7(17):5152-5155.

Reg3α concentrations at day of allogeneic stem cell transplantation predict outcome and correlate with early antibiotic use
Weber D, Weber M, Meedt E, Ghimire S, Wolff D, Edinger M, Poeck H, Hiergeist A, Gessner A, Ayuk F, Roesler W, Wolfl M, Kraus S, Zeiser R, Bertrand H, Bader P, Ullrich E, Eder M, Gleich S, Young R, Herr W, Levine J, Ferrara J, Holler E
BLOOD ADV. 2023;7(7):1326-1335.

Pathophysiology of gastrointestinal acute graft-versus-host disease and the potential role of glucagon-like peptide 2
Zeiser R, Chen Y, Youssef N, Ayuk F
BRIT J HAEMATOL. 2023;201(4):620-627.

2022

Management of Cytokine Release Syndrome (CRS) and HLH
Ayuketang F, Jäger U
2022. The EBMT/EHA CAR-T Cell Handbook. Kröger N, Gribben J, Chabannon C, Yakoub-Agha I, Einsele H (Hrsg.). 1. Aufl. Cham: Springer International Publishing, 135-139.

GLA/DRST real-world outcome analysis of CAR-T cell therapies for large B-cell lymphoma in Germany
Bethge W, Martus P, Schmitt M, Holtick U, Subklewe M, von Tresckow B, Ayuk F, Wagner-Drouet E, Wulf G, Marks R, Penack O, Schnetzke U, Koenecke C, von Bonin M, Stelljes M, Glass B, Baldus C, Vucinic V, Mougiakakos D, Topp M, Fante M, Schroers R, Bayir L, Borchmann P, Buecklein V, Hanoun C, Thomas S, Beelen D, Lengerke C, Kroeger N, Dreger P
BLOOD. 2022;140(4):349-358.

Iron Chelation with Deferasirox increases Busulfan AUC during Conditioning Chemotherapy prior to Allogeneic Stem Cell Transplantation
Essmann S, Dadkhah A, Janson D, Wolschke C, Ayuk F, Kröger N, Langebrake C
TRANSPL CELL THER. 2022;28(2):115.e1-115.e5.

Assessment of systemic and gastrointestinal tissue damage biomarkers for GVHD risk stratification
Etra A, Gergoudis S, Morales G, Spyrou N, Shah J, Kowalyk S, Ayuk F, Baez J, Chanswangphuwana C, Chen Y, Choe H, DeFilipp Z, Gandhi I, Hexner E, Hogan W, Holler E, Kapoor U, Kitko C, Kraus S, Lin J, Al Malki M, Merli P, Pawarode A, Pulsipher M, Qayed M, Reshef R, Rösler W, Schechter T, Van Hyfte G, Weber D, Wölfl M, Young R, Özbek U, Ferrara J, Levine J
BLOOD ADV. 2022;6(12):3707-3715.

Impact of in vivo T-cell depletion in patients with myelodysplastic syndromes undergoing allogeneic hematopoietic stem cell transplant: a registry study from the Chronic Malignancies Working Party of the EBMT
Forcade E, Chevret S, Finke J, Ehninger G, Ayuk F, Beelen D, Koster L, Ganser A, Volin L, Sengeloev H, Michallet M, Tischer J, Jindra P, Cascon M, Koc Y, Arat M, Tomaszewska A, Hayden P, de Witte T, Yakoub-Agha I, Kröger N, Robin M
BONE MARROW TRANSPL. 2022;57(5):768-774.

Antibody response after vaccination against SARS-CoV-2 in adults with hematological malignancies: a systematic review and meta-analysis
Gagelmann N, Passamonti F, Wolschke C, Massoud R, Niederwieser C, Adjallé R, Mora B, Ayuk F, Kröger N
HAEMATOLOGICA. 2022;107(8):1840-1849.

Reduced intensity hematopoietic stem cell transplantation for accelerated-phase myelofibrosis
Gagelmann N, Wolschke C, Salit R, Schroeder T, Ditschkowski M, Panagiota V, Cassinat B, Thol F, Badbaran A, Robin M, Reinhardt H, Ayuk F, Heuser M, Scott B, Kröger N
BLOOD ADV. 2022;6(4):1222-1231.

Clinical features of hepatitis E infections in patients with hematologic disorders
Ghandili S, Lindhauer C, Pischke S, Zur Wiesch J, Von Kroge P, Polywka S, Bokemeyer C, Fiedler W, Kröger N, Ayuk F, Adjallé R, Modemann F
HAEMATOLOGICA. 2022;107(12):2870-2883.

Extracorporeal photopheresis in acute and chronic steroid‑refractory graft-versus-host disease: an evolving treatment landscape
Greinix H, Ayuk F, Zeiser R
LEUKEMIA. 2022;36(11):2558-2566.

Post-Transplantation Multicolored Flow Cytometry-Minimal Residual Disease Status on Day 100 Predicts Outcomes for Patients With Refractory Acute Myeloid Leukemia
Klyuchnikov E, Badbaran A, Massoud R, Fritsche-Friedland U, Janson D, Ayuk F, Christopeit M, Wolschke C, Bacher U, Kröger N
TRANSPL CELL THER. 2022;28(5):267.e1-267.e7.

Post-Transplantation Day +100 Minimal Residual Disease Detection Rather Than Mixed Chimerism Predicts Relapses after Allogeneic Stem Cell Transplantation for Intermediate-Risk Acute Myelogenous Leukemia Patients Undergoing Transplantation in Complete Remission
Klyuchnikov E, Badbaran A, Massoud R, Fritzsche-Friedland U, Freiberger P, Ayuk F, Wolschke C, Bacher U, Kröger N
TRANSPL CELL THER. 2022;28(7):374.e1-374.e9.

Comparison of immune reconstitution between anti-T-lymphocyte globulin and post-transplant cyclophosphamide as acute graft-versus-host disease prophylaxis in allogeneic myeloablative peripheral blood stem cell transplantation
Massoud R, Gagelmann N, Fritzsche-Friedland U, Zeck G, Heidenreich S, Wolschke C, Ayuk F, Christopeit M, Kröger N
HAEMATOLOGICA. 2022;107(4):857-867.

Impact of Anti-T-lymphocyte globulin dosing on GVHD and Immune reconstitution in matched unrelated myeloablative peripheral blood stem cell transplantation
Massoud R, Klyuchnikov E, Gagelmann N, Zabelina T, Wolschke C, Ayuk F, Fritzsche-Friedland U, Zander A, Kröger N
BONE MARROW TRANSPL. 2022;57(10):1548-1555.

Endothelial complications after allogeneic stem cell transplantation in patients with pretransplant resolved COVID-19
Niederwieser C, Weber B, Reichard M, Gagelmann N, Ajib S, Schlipfenbacher V, Zeng Z, Lang F, Janson D, Wolschke C, Ayuk F, Bug G, Kröger N
BONE MARROW TRANSPL. 2022;57(7):1180-1182.

Comparison of single copy gene‑based duplex quantitative PCR and digital droplet PCR for monitoring of expansion of CD19‑directed CAR T cells in treated patients
Schubert M, Berger C, Kunz A, Schmitt A, Badbaran A, Neuber B, Zeschke S, Wang L, Riecken K, Hückelhoven-Krauss A, Müller I, Müller-Tidow C, Dreger P, Kröger N, Ayuk F, Schmitt M, Fehse B
INT J ONCOL. 2022;60(5):.

2021

Axicabtagene ciloleucel in vivo expansion and treatment outcome in aggressive B-cell lymphoma in a real-world setting
Ayuk F, Berger C, Badbaran A, Zabelina T, Sonntag T, Riecken K, Geffken M, Wichmann D, Frenzel C, Thayssen G, Zeschke S, Kröger N, Fehse B
BLOOD ADV. 2021;5(11):2523-2527.

Allogeneic stem cell transplantation in acute leukemia patients after COVID-19 infection
Christopeit M, Reichard M, Niederwieser C, Massoud R, Klyuchnikov E, Haase N, Wolschke C, Ayuk F, Heidenreich S, Kröger N
BONE MARROW TRANSPL. 2021;56(6):1478-1481.

Immune Monitoring Assay for Extracorporeal Photopheresis Treatment Optimization After Heart Transplantation
Dieterlen M, Klaeske K, Bernhardt A, Borger M, Klein S, Garbade J, Lehmann S, Ayuk F, Reichenspurner H, Barten M
FRONT IMMUNOL. 2021;12:.

TKI Maintenance After Stem-Cell Transplantation for FLT3-ITD Positive Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis
Gagelmann N, Wolschke C, Klyuchnikov E, Christopeit M, Ayuk F, Kröger N
FRONT IMMUNOL. 2021;12:.

Erratum zu: Toxizitäten nach Chimärer-Antigenrezeptor-T-Zell-Therapie
Garcia Borrega J, Heindel K, Göreci Y, Warnke C, Onur O, Kochanek M, Schub N, Ayuk F, Wichmann D, Böll B
INTERNIST. 2021;62(6):694.

Toxizitäten nach Chimärer-Antigenrezeptor-T-Zell-Therapie : Übersicht und Management früher und verzögerter Nebenwirkungen
Garcia Borrega J, Heindel K, Göreci Y, Warnke C, Onur O, Kochanek M, Schub N, Ayuk F, Wichmann D, Böll B
INTERNIST. 2021;62(6):611-619.

Hepatitis E virus persists in the ejaculate of chronically infected men
Horvatits T, Wißmann J, Johne R, Groschup M, Gadicherla A, Wiesch J, Eiden M, Todt D, Reimer R, Dähnert L, Schöbel A, Horvatits K, Lübke R, Wolschke C, Ayuk F, Rybczynski M, Lohse A, Addo M, Herker E, Lütgehetmann M, Steinmann E, Pischke S
J HEPATOL. 2021;75(1):55-63.

Enhanced Immune Reconstitution of γδ T Cells after Allogeneic Stem Cell Transplantation Overcomes the Negative Impact of Pretransplantation Minimal Residual Disease-Positive Status in Patients with Acute Myelogenous Leukemia
Klyuchnikov E, Badbaran A, Massoud R, Fritsche-Friedland U, Janson D, Ayuk F, Wolschke C, Bacher U, Kröger N
TRANSPL CELL THER. 2021;27(10):841-850.

Correction: Ruxolitinib plus extracorporeal photopheresis (ECP) for steroid refractory acute graft-versus-host disease of lower GI-tract after allogeneic stem cell transplantation leads to increased regulatory T cell level
Modemann F, Ayuk F, Wolschke C, Christopeit M, Janson D, von Pein U, Kröger N
BONE MARROW TRANSPL. 2021;56(10):2617.

Risk factors for outcome after allogeneic stem cell transplantation in patients with advanced phase CML
Niederwieser C, Morozova E, Zubarovskaya L, Zabelina T, Klyuchnikov E, Janson D, Wolschke C, Christopeit M, Ayuk F, Moiseev I, Afanasyev B, Kröger N
BONE MARROW TRANSPL. 2021;56(11):2834-2841.

1,25-dihydroxyvitamin-D3 but not the clinically applied marker 25-hydroxyvitamin-D3 predicts survival after stem cell transplantation
Peter K, Siska P, Roider T, Matos C, Bruns H, Renner K, Singer K, Weber D, Güllstorf M, Kröger N, Wolff D, Herr W, Ayuk F, Holler E, Stark K, Heid I, Kreutz M
BONE MARROW TRANSPL. 2021;56(2):419-433.

National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIb. The 2020 Preemptive Therapy Working Group Report
Pidala J, Kitko C, Lee S, Carpenter P, Cuvelier G, Holtan S, Flowers M, Cutler C, Jagasia M, Gooley T, Palmer J, Randolph T, Levine J, Ayuk F, Dignan F, Schoemans H, Tkaczyk E, Farhadfar N, Lawitschka A, Schultz K, Martin P, Sarantopoulos S, Inamoto Y, Socie G, Wolff D, Blazar B, Greinix H, Paczesny S, Pavletic S, Hill G
TRANSPL CELL THER. 2021;27(8):632-641.

CAR-HEMATOTOX: A model for CAR T-cell related hematological toxicity in relapsed/refractory large B-cell lymphoma
Rejeski K, Perez Perez A, Sesques P, Hoster E, Berger C, Jentzsch L, Mougiakakos D, Frölich L, Ackermann J, Buecklein V, Blumenberg V, Schmidt C, Jallades L, Fehse B, Faul C, Karschnia P, Weigert O, Dreyling M, Locke F, von Bergwelt-Baildon M, Mackensen A, Bethge W, Ayuk F, Bachy E, Salles G, Jain M, Subklewe M
BLOOD. 2021;138(24):2499-2513.

Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group
Spanjaart A, Ljungman P, de La Camara R, Tridello G, Ortiz-Maldonado V, Urbano-Ispizua A, Barba P, Kwon M, Caballero D, Sesques P, Bachy E, Di Blasi R, Thieblemont C, Calkoen F, Mutsaers P, Maertens J, Giannoni L, Nicholson E, Collin M, Vaz C, Metafuni E, Martinez-Lopez J, Dignan F, Ribera J, Nagler A, Folber F, Sanderson R, Bloor A, Ciceri F, Knelange N, Ayuk F, Kroger N, Kersten M, Mielke S
LEUKEMIA. 2021;35(12):3585-3588.

Evaluation of Elafin as a Prognostic Biomarker in Acute Graft-versus-Host Disease
Zewde M, Morales G, Gandhi I, Özbek U, Aguayo-Hiraldo P, Ayuk F, Baez J, Chanswangphuwana C, Choe H, DeFilipp Z, Etra A, Grupp S, Hexner E, Hogan W, Javorniczky N, Kasikis S, Kitko C, Kowalyk S, Meedt E, Merli P, Nakamura R, Qayed M, Reshef R, Rösler W, Schechter T, Weber D, Wölfl M, Yanik G, Young R, Levine J, Ferrara J, Chen Y
TRANSPL CELL THER. 2021;27(12):988.e1-988.e7.

2020

Incidence and Outcome of Late Relapse after Allogeneic Stem Cell Transplantation for Myelofibrosis
Atagunduz I, Christopeit M, Ayuk F, Zeck G, Wolschke C, Kröger N
BIOL BLOOD MARROW TR. 2020;26(12):2279-2284.

Treosulfan-Based Conditioning Regimen for Second Allograft in Patients with Myelofibrosis
Atagunduz I, Klyuchnikov E, Wolschke C, Janson D, Heidenreich S, Christopeit M, Ayuk F, Kröger N
CANCERS. 2020;12(11):.

Excellent proliferation and persistence of allogeneic donor-derived 41-BB based CAR-T cells despite immunosuppression with cyclosporine A
Ayuk F, Fehse B, Janson D, Berger C, Riecken K, Kröger N
HAEMATOLOGICA. 2020;105(6):322-324.

Disease risk and GVHD biomarkers can stratify patients for risk of relapse and nonrelapse mortality post hematopoietic cell transplant
Aziz M, Shah J, Kapoor U, Dimopoulos C, Anand S, Augustine A, Ayuk F, Chaudhry M, Chen Y, Choe H, Etra A, Gergoudis S, Hartwell M, Hexner E, Hogan W, Kitko C, Kowalyk S, Kröger N, Merli P, Morales G, Nakamura R, Ordemann R, Pulsipher M, Qayed M, Reshef R, Rösler W, Schechter T, Schreiner E, Srinagesh H, Wölfl M, Wudhikarn K, Yanik G, Young R, Özbek U, Ferrara J, Levine J
LEUKEMIA. 2020;34(7):1898-1906.

Accurate In-Vivo Quantification of CD19 CAR-T Cells after Treatment with Axicabtagene Ciloleucel (Axi-Cel) and Tisagenlecleucel (Tisa-Cel) Using Digital PCR
Badbaran A, Berger C, Riecken K, Kruchen A, Geffken M, Müller I, Kröger N, Ayuk F, Fehse B
CANCERS. 2020;12(7):.

Digital PCR Assays for Precise Quantification of CD19-CAR-T Cells after Treatment with Axicabtagene Ciloleucel
Fehse B, Badbaran A, Berger C, Sonntag T, Riecken K, Geffken M, Kröger N, Ayuk F
MOL THER-METH CLIN D. 2020;16:172-178.

B cell maturation antigen-specific chimeric antigen receptor T cells for relapsed or refractory multiple myeloma
Gagelmann N, Ayuk F, Atanackovic D, Kröger N
EUR J HAEMATOL. 2020;104(4):318-327.

Development of CAR-T cell therapies for multiple myeloma
Gagelmann N, Riecken K, Wolschke C, Berger C, Ayuk F, Fehse B, Kröger N
LEUKEMIA. 2020;34(9):2317-2332.

Biomarker-guided preemption of steroid-refractory graft-versus-host disease with α-1-antitrypsin
Gergoudis S, DeFilipp Z, Özbek U, Sandhu K, Etra A, Choe H, Kitko C, Ayuk F, Aziz M, Baez J, Ben-David K, Bunworasate U, Gandhi I, Hexner E, Hogan W, Holler E, Kasikis S, Kowalyk S, Lin J, Merli P, Morales G, Nakamura R, Reshef R, Rösler W, Srinagesh H, Young R, Chen Y, Ferrara J, Levine J
BLOOD ADV. 2020;4(24):6098-6105.

Major central nervous system complications after allogeneic stem cell transplantation: a large retrospective study on 888 consecutive adult patients
Mannina D, Berneking L, Both A, Timm W, Urbanowicz T, Wolschke C, Ayuk F, Fischer N, Fiehler J, Grzyska U, Rösner S, Choe C, Kröger N, Christopeit M
EUR J HAEMATOL. 2020;105(6):722-730.

Ruxolitinib plus extracorporeal photopheresis (ECP) for steroid refractory acute graft-versus-host disease of lower GI-tract after allogeneic stem cell transplantation leads to increased regulatory T cell level
Modemann F, Ayuk F, Wolschke C, Christopeit M, Janson D, von Pein U, Kröger N
BONE MARROW TRANSPL. 2020;55(12):2286-2293.

Glucagon like peptide-2 for Intestinal stem cell and Paneth cell repair during graft-versus-host disease in mice and humans
Norona J, Apostolova P, Schmidt D, Ihlemann R, Reischmann N, Taylor G, Köhler N, de Heer J, Heeg S, Andrieux G, Siranosian B, Schmitt-Graeff A, Pfeifer D, Catalano A, Frew I, Proietti M, Grimbacher B, Bulashevska A, Bhatt A, Brummer T, Clauditz T, Zabelina T, Kroeger N, Blazar B, Boerries M, Ayuk F, Zeiser R
BLOOD. 2020;136(12):1442-1455.

Second allogeneic stem cell transplantation for relapse after allografting in multiple myeloma using CD 34+ selected donor cells without immunosuppression
Novak P, Klyuchnikov E, von Pein U, Güllstorf M, Christopeit M, Ayuk F, Geffken M, Wolschke C, Kröger N
BONE MARROW TRANSPL. 2020;55(9):1817-1820.

Allogeneic Stem Cell Transplantation for Patients with Lower-Risk Myelodysplastic Syndrome
Novak P, Zabelina T, Wolschke C, Ayuk F, Christopeit M, Kröger N
BIOL BLOOD MARROW TR. 2020;26(11):2047-2052.

Monocenter study on epidemiology, outcomes, and risk factors of infections in recipients of 166 allogeneic stem cell transplantations during 1 year
Samek M, Iversen K, Belmar Campos C, Berneking L, Langebrake C, Wolschke C, Ayuk F, Kröger N, Christopeit M
EUR J HAEMATOL. 2020;105(2):126-137.

External Validation of Models for KIR2DS1/KIR3DL1-informed Selection of Hematopoietic Cell Donors fails
Schetelig J, Baldauf H, Heidenreich F, Massalski C, Frank S, Sauter J, Stelljes M, Ayuk F, Bethge W, Bug G, Klein S, Wendler S, Lange V, de Wreede L, Fuerst D, Kobbe G, Ottinger H, Beelen D, Mytilineos J, Fleischhauer K, Schmidt A, Bornhauser M
BLOOD. 2020;135(16):1386-1395.

Nanobody-based CD38-specific heavy chain antibodies induce killing of multiple myeloma and other hematological malignancies
Schriewer L, Schütze K, Petry K, Hambach J, Fumey W, Koenigsdorf J, Baum N, Menzel S, Rissiek B, Riecken K, Fehse B, Röckendorf J, Schmid J, Albrecht B, Pinnschmidt H, Ayuk F, Kröger N, Binder M, Schuch G, Hansen T, Haag F, Adam G, Koch-Nolte F, Bannas P
THERANOSTICS. 2020;10(6):2645-2658.

Benchmarking of survival outcomes following haematopoietic stem cell transplantation: A review of existing processes and the introduction of an international system from the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)
Snowden J, Saccardi R, Orchard K, Ljungman P, Duarte R, Labopin M, McGrath E, Brook N, de Elvira C, Gordon D, Poirel H, Ayuk F, Beguin Y, Bonifazi F, Gratwohl A, Milpied N, Moore J, Passweg J, Rizzo J, Spellman S, Sierra J, Solano C, Sanchez-Guijo F, Worel N, Gusi A, Adams G, Balan T, Baldomero H, Macq G, Marry E, Mesnil F, Oldani E, Pearce R, Perry J, Raus N, Schanz U, Tran S, Wilcox L, Basak G, Chabannon C, Corbacioglu S, Dolstra H, Kuball J, Mohty M, Lankester A, Montoto S, Nagler A, Styczynski J, Yakoub-Agha I, de Latour R, Kroeger N, Brand R, de Wreede L, van Zwet E, Putter H
BONE MARROW TRANSPL. 2020;55(4):681-694.

Correction: Benchmarking of survival outcomes following haematopoietic stem cell transplantation: A review of existing processes and the introduction of an international system from the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)
Snowden J, Saccardi R, Orchard K, Ljungman P, Duarte R, Labopin M, McGrath E, Brook N, de Elvira C, Gordon D, Poirel H, Ayuk F, Beguin Y, Bonifazi F, Gratwohl A, Milpied N, Moore J, Passweg J, Rizzo J, Spellman S, Sierra J, Solano C, Sanchez-Guijo F, Worel N, Gusi A, Adams G, Balan T, Baldomero H, Macq G, Marry E, Mesnil F, Oldani E, Pearce R, Perry J, Raus N, Schanz U, Tran S, Wilcox L, Basak G, Chabannon C, Corbacioglu S, Dolstra H, Kuball J, Mohty M, Lankester A, Montoto S, Nagler A, Styczynski J, Yakoub-Agha I, de Latour R, Kroeger N, Brand R, de Wreede L, van Zwet E, Putter H
BONE MARROW TRANSPL. 2020;55(4):838-839.

Evaluation of the Cost of Survivorship Care After Allogeneic Hematopoeitic Stem Cell Transplantation-An Analysis of 2 German Transplantation Centers
Wolff D, Bardak J, Edinger M, Klinger-Schindler U, Holler E, Lawitschka A, Schoemans H, Herr W, Kröger N, Ayuk Ayuketang F
FRONT PUBLIC HEALTH. 2020;8:572470.

2019

Donor Selection for Adults and Pediatrics
Ayuk F, Balduzzi A
2019. The EBMT Handbook: Hematopoietic Stem Cell Transplantation and Cellular Therapies. Carreras E, Dufour C, Mohty M, Kröger N (Hrsg.). Springer Nature Switzerland AG, 87-97.

Predicted Indirectly ReCognizable HLA Epitopes (PIRCHE) Are Associated with Poorer Outcome after Single Mismatch Unrelated Donor Stem Cell Transplantation: A Study of the Cooperative Transplant Study Group (KTS) of the German Group for Bone Marrow and Stem Cell Transplantation (DAG-KBT)
Ayuk F, Bornhäuser M, Stelljes M, Zabelina T, Wagner E, Schmid C, Christopeit M, Guellstorf M, Kröger N, Bethge W
TRANSFUS MED HEMOTH. 2019;46(5):370-375.

Chancen und Risiken der CAR-T-Zell-Therapie
Ayuk F, Fehse B, Berger S, Riecken K, Kroger N
Hamb Ärztebl. 2019;73(10):30-32.

Skin, Hair and Musculosceletal Complications
Ayuk F, Savani B
2019. The EBMT Handbook. Carreras E, Dufour C, Mohty M, Kröger N (Hrsg.). 1. Aufl. Switzerland: Springer Open, 409-414.

Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study
Bonifazi F, Solano C, Wolschke C, Sessa M, Patriarca F, Zallio F, Nagler A, Selleri C, Risitano A, Messina G, Bethge W, Herrera P, Sureda A, Carella A, Cimminiello M, Guidi S, Finke J, Sorasio R, Ferra C, Sierra J, Russo D, Benedetti E, Milone G, Benedetti F, Heinzelmann M, Pastore D, Jurado M, Terruzzi E, Narni F, Völp A, Ayuk F, Ruutu T, Kröger N
LANCET HAEMATOL. 2019;6(2):e89-e99.

Allogeneic stem cell transplantation for myelofibrosis patients aged ≥65 years
Daghia G, Zabelina T, Zeck G, von Pein U, Christopeit M, Wolschke C, Ayuk F, Kröger N
EUR J HAEMATOL. 2019;103(4):370-378.

Role of Donor Clonal Hematopoiesis in Allogeneic Hematopoietic Stem-Cell Transplantation
Frick M, Chan W, Arends C, Hablesreiter R, Halik A, Heuser M, Michonneau D, Blau O, Hoyer K, Christen F, Galan-Sousa J, Noerenberg D, Wais V, Stadler M, Yoshida K, Schetelig J, Schuler E, Thol F, Clappier E, Christopeit M, Ayuk F, Bornhäuser M, Blau I, Ogawa S, Zemojtel T, Gerbitz A, Wagner E, Spriewald B, Schrezenmeier H, Kuchenbauer F, Kobbe G, Wiesneth M, Koldehoff M, Socié G, Kroeger N, Bullinger L, Thiede C, Damm F
J CLIN ONCOL. 2019;37(5):375-385.

Unklare Panzytopenie bei einem 52-jährigen Patienten
Heidenreich S, van Randenbourgh A, Ayuk F, Kröger N, Schmiedel S, Asemissen A, Oelrich J, Wolschke C
INTERNIST. 2019;60(8):867-870.

Randomized controlled study of ECP with methoxsalen as first-line treatment of patients with moderate to severe cGVHD
Jagasia M, Scheid C, Socié G, Ayuk F, Tischer J, Donato M, Bátai Á, Chen H, Chen S, Chin T, Boodée H, Mitri G, Greinix H
BLOOD ADV. 2019;3(14):2218-2229.

Reduced intensity allogeneic stem cell transplantation for younger patients with myelofibrosis
Mannina D, Zabelina T, Wolschke C, Heinzelmann M, Triviai I, Christopeit M, Badbaran A, Bonmann S, von Pein U, Janson D, Ayuk F, Kröger N
BRIT J HAEMATOL. 2019;186(3):484-489.

Allogeneic Stem Cell Transplantation for Blast Crisis Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: A Retrospective Study by the EBMT Chronic Malignancies Working Party
Radujkovic A, Dietrich S, Blok H, Nagler A, Ayuk F, Finke J, Tischer J, Mayer J, Koc Y, Sorà F, Passweg J, Byrne J, Jindra P, Veelken J, Socié G, Maertens J, Schaap N, Stadler M, Itälä-Remes M, Tholouli E, Arat M, Rocha V, Ljungman P, Yakoub-Agha I, Kröger N, Chalandon Y
BIOL BLOOD MARROW TR. 2019;25(10):2008-2016.

The MAGIC algorithm probability is a validated response biomarker of treatment of acute graft-versus-host disease
Srinagesh H, Özbek U, Kapoor U, Ayuk F, Aziz M, Ben-David K, Choe H, DeFilipp Z, Etra A, Grupp S, Hartwell M, Hexner E, Hogan W, Karol A, Kasikis S, Kitko C, Kowalyk S, Lin J, Major-Monfried H, Mielke S, Merli P, Morales G, Ordemann R, Pulsipher M, Qayed M, Reddy P, Reshef R, Rösler W, Sandhu K, Schechter T, Shah J, Sigel K, Weber D, Wölfl M, Wudhikarn K, Young R, Levine J, Ferrara J
BLOOD ADV. 2019;3(23):4034-4042.

The burden of hepatitis E among patients with haematological malignancies: A retrospective European cohort study
von Felden J, Alric L, Pischke S, Aitken C, Schlabe S, Spengler U, Giordani M, Schnitzler P, Bettinger D, Thimme R, Xhaard A, Binder M, Ayuk F, Lohse A, Cornelissen J, de Man R, Mallet V
J HEPATOL. 2019;71(3):465-472.

Changes in Immunosuppressive Treatment of Chronic Graft-versus-Host Disease: Comparison of 2 Surveys within Allogeneic Hematopoietic Stem Cell Transplant Centers in Germany, Austria, and Switzerland
Wolff D, Hilgendorf I, Wagner-Drouet E, Jedlickova Z, Ayuk F, Zeiser R, Schäfer-Eckart K, Gerbitz A, Stadler M, Klein S, Middeke J, Lawitschka A, Winkler J, Halter J, Holler E, Kobbe G, Stelljes M, Ditschkowski M, Greinix H
BIOL BLOOD MARROW TR. 2019;25(7):1450-1455.

2018

Langzeitnachsorge von Patienten nach allogener Blutstammzelltransplantation
Ayuketang F, Kroger N
2018. Langzeitnachsorge von Patienten nach allogener Blutstammzelltransplantation. Ayuk F, Kröger N, Tichelli A (Hrsg.). 1.. Aufl. Uni-Med, .

Relative Impact of HLA Matching and Non-HLA Donor Characteristics on Outcomes of Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndrome
Ayuk F, Beelen D, Bornhäuser M, Stelljes M, Zabelina T, Finke J, Kobbe G, Wolff D, Wagner E, Christopeit M, Schmid C, Ottinger H, Groth C, Faul C, Bertz H, Rachlis E, Wolschke C, Schetelig J, Horn P, Mytilineos J, Guellstorf M, Kelsch R, Fleischhauer K, Kröger N, Bethge W
BIOL BLOOD MARROW TR. 2018;24(12):2558-2567.

Allogeneic hematopoietic cell transplantation in Farber disease
Ehlert K, Levade T, Di Rocco M, Lanino E, Albert M, Führer M, Jarisch A, Güngör T, Ayuk F, Vormoor J
J INHERIT METAB DIS. 2018 [Epub ahead of print].

An early-biomarker algorithm predicts lethal graft-versus-host disease and survival
Hartwell M, Özbek U, Holler E, Renteria A, Major-Monfried H, Reddy P, Aziz M, Hogan W, Ayuk F, Efebera Y, Hexner E, Bunworasate U, Qayed M, Ordemann R, Wölfl M, Mielke S, Pawarode A, Chen Y, Devine S, Harris A, Jagasia M, Kitko C, Litzow M, Kröger N, Locatelli F, Morales G, Nakamura R, Reshef R, Rösler W, Weber D, Wudhikarn K, Yanik G, Levine J, Ferrara J
JCI INSIGHT. 2018;3(16):.

Amphiregulin modifies the Minnesota Acute Graft-versus-Host Disease Risk Score: results from BMT CTN 0302/0802
Holtan S, DeFor T, Panoskaltsis-Mortari A, Khera N, Levine J, Flowers M, Lee S, Inamoto Y, Chen G, Mayer S, Arora M, Palmer J, Cutler C, Arai S, Lazaryan A, Newell L, Jagasia M, Pusic I, Wood W, Renteria A, Yanik G, Hogan W, Hexner E, Ayuk F, Holler E, Bunworasate U, Efebera Y, Ferrara J, Pidala J, Howard A, Wu J, Bolaños-Meade J, Ho V, Alousi A, Blazar B, Weisdorf D, MacMillan M
BLOOD ADV. 2018;2(15):1882-1888.

Peritransplantation Ruxolitinib Prevents Acute Graft-versus-Host Disease in Patients with Myelofibrosis Undergoing Allogenic Stem Cell Transplantation
Kröger N, Shahnaz Syed Abd Kadir S, Zabelina T, Badbaran A, Christopeit M, Ayuk F, Wolschke C
BIOL BLOOD MARROW TR. 2018;24(10):2152-2156.

MAGIC biomarkers predict long term outcomes for steroid-resistant acute GVHD
Major-Monfried H, Renteria A, Pawarode A, Reddy P, Ayuk F, Holler E, Efebera Y, Hogan W, Wölfl M, Qayed M, Hexner E, Wudhikarn K, Ordemann R, Young R, Shah J, Hartwell M, Chaudhry M, Aziz M, Etra A, Yanik G, Kröger N, Weber D, Chen Y, Nakamura R, Rösler W, Kitko C, Harris A, Pulsipher M, Reshef R, Kowalyk S, Morales G, Torres I, Özbek U, Ferrara J, Levine J
BLOOD. 2018;131(25):2846-2855.

Erratum: Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells
Mathew N, Baumgartner F, Braun L, O'Sullivan D, Thomas S, Waterhouse M, Müller T, Hanke K, Taromi S, Apostolova P, Illert A, Melchinger W, Duquesne S, Schmitt-Graeff A, Osswald L, Yan K, Weber A, Tugues S, Spath S, Pfeifer D, Follo M, Claus R, Lübbert M, Rummelt C, Bertz H, Wäsch R, Haag J, Schmidts A, Schultheiss M, Bettinger D, Thimme R, Ullrich E, Tanriver Y, Vuong G, Arnold R, Hemmati P, Wolf D, Ditschkowski M, Jilg C, Wilhelm K, Leiber C, Gerull S, Halter J, Lengerke C, Pabst T, Schroeder T, Kobbe G, Rösler W, Doostkam S, Meckel S, Stabla K, Metzelder S, Halbach S, Brummer T, Hu Z, Dengjel J, Hackanson B, Schmid C, Holtick U, Scheid C, Spyridonidis A, Stölzel F, Ordemann R, Müller L, Sicre-de-Fontbrune F, Ihorst G, Kuball J, Ehlert J, Feger D, Wagner E, Cahn J, Schnell J, Kuchenbauer F, Bunjes D, Chakraverty R, Richardson S, Gill S, Kröger N, Ayuk F, Vago L, Ciceri F, Müller A, Kondo T, Teshima T, Klaeger S, Kuster B, Kim D, Weisdorf D, van der Velden W, Dörfel D, Bethge W, Hilgendorf I, Hochhaus A, Andrieux G, Börries M, Busch H, Magenau J, Reddy P, Labopin M, Antin J, Henden A, Hill G, Kennedy G, Bar M, Sarma A, McLornan D, Mufti G, Oran B, Rezvani K, Shah O, Negrin R, Nagler A, Prinz M, Burchert A, Neubauer A, Beelen D, Mackensen A, von Bubnoff N, Herr W, Becher B, Socié G, Caligiuri M, Ruggiero E, Bonini C, Häcker G, Duyster J, Finke J, Pearce E, Blazar B, Zeiser R
NAT MED. 2018;24(4):526.

Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells
Mathew N, Baumgartner F, Braun L, O'Sullivan D, Thomas S, Waterhouse M, Müller T, Hanke K, Taromi S, Apostolova P, Illert A, Melchinger W, Duquesne S, Schmitt-Graeff A, Osswald L, Yan K, Weber A, Tugues S, Spath S, Pfeifer D, Follo M, Claus R, Lübbert M, Rummelt C, Bertz H, Wäsch R, Haag J, Schmidts A, Schultheiss M, Bettinger D, Thimme R, Ullrich E, Tanriver Y, Vuong G, Arnold R, Hemmati P, Wolf D, Ditschkowski M, Jilg C, Wilhelm K, Leiber C, Gerull S, Halter J, Lengerke C, Pabst T, Schroeder T, Kobbe G, Rösler W, Doostkam S, Meckel S, Stabla K, Metzelder S, Halbach S, Brummer T, Hu Z, Dengjel J, Hackanson B, Schmid C, Holtick U, Scheid C, Spyridonidis A, Stölzel F, Ordemann R, Müller L, Sicre-de-Fontbrune F, Ihorst G, Kuball J, Ehlert J, Feger D, Wagner E, Cahn J, Schnell J, Kuchenbauer F, Bunjes D, Chakraverty R, Richardson S, Gill S, Kröger N, Ayuk F, Vago L, Ciceri F, Müller A, Kondo T, Teshima T, Klaeger S, Kuster B, Kim D, Weisdorf D, van der Velden W, Dörfel D, Bethge W, Hilgendorf I, Hochhaus A, Andrieux G, Börries M, Busch H, Magenau J, Reddy P, Labopin M, Antin J, Henden A, Hill G, Kennedy G, Bar M, Sarma A, McLornan D, Mufti G, Oran B, Rezvani K, Shah O, Negrin R, Nagler A, Prinz M, Burchert A, Neubauer A, Beelen D, Mackensen A, von Bubnoff N, Herr W, Becher B, Socié G, Caligiuri M, Ruggiero E, Bonini C, Häcker G, Duyster J, Finke J, Pearce E, Blazar B, Zeiser R
NAT MED. 2018;24(3):282-291.

Impact of ruxolitinib pretreatment on outcomes after allogeneic stem cell transplantation in patients with myelofibrosis
Shahnaz Syed Abd Kadir S, Christopeit M, Wulf G, Wagner E, Bornhauser M, Schroeder T, Crysandt M, Mayer K, Jonas J, Stelljes M, Badbaran A, Ayuketang Ayuk F, Triviai I, Wolf D, Wolschke C, Kröger N
EUR J HAEMATOL. 2018;101(3):305-317.

HEV-positive blood donations represent a relevant infection risk for immunosuppressed recipients
Westhölter D, Hiller J, Denzer U, Polywka S, Ayuk F, Rybczynski M, Horvatits T, Gundlach S, Blöcker J, Schulze Zur Wiesch J, Fischer N, Addo M, Peine S, Göke B, Lohse A, Lütgehetmann M, Pischke S
J HEPATOL. 2018;69(1):36-42.

2017

Comparison of Different Rabbit Anti-Thymocyte Globulin Formulations in Allogeneic Stem Cell Transplantation: Systematic Literature Review and Network Meta-Analysis
Gagelmann N, Ayuk F, Wolschke C, Kröger N
BIOL BLOOD MARROW TR. 2017;23(12):2184-2191.

An early-biomarker algorithm predicts lethal graft-versus-host disease and survival
Hartwell M, Özbek U, Holler E, Renteria A, Major-Monfried H, Reddy P, Aziz M, Hogan W, Ayuketang F, Efebera Y, Hexner E, Bunworasate U, Qayed M, Ordemann R, Wölfl M, Mielke S, Pawarode A, Chen Y, Devine S, Harris A, Jagasia M, Kitko C, Litzow M, Kröger N, Locatelli F, Morales G, Nakamura R, Reshef R, Rösler W, Weber D, Wudhikarn K, Yanik G, Levine J, Ferrara J
JCI INSIGHT. 2017;2(3):e89798.

Impact of Molecular Genetics on Outcome in Myelofibrosis Patients after Allogeneic Stem Cell Transplantation
Kröger N, Panagiota V, Badbaran A, Zabelina T, Triviai I, Araujo Cruz M, Shahswar R, Ayuketang F, Gehlhaar M, Wolschke C, Bollin R, Walter C, Dugas M, Wiehlmann L, Lehmann U, Koenecke C, Chaturvedi A, Alchalby H, Stadler M, Eder M, Christopeit M, Göhring G, Koenigsmann M, Schlegelberger B, Kreipe H, Ganser A, Stocking C, Fehse B, Thol F, Heuser M
BIOL BLOOD MARROW TR. 2017;23(7):1095-1101.

Impact of molecular residual disease post allografting in myelofibrosis patients
Wolschke C, Badbaran A, Zabelina T, Christopeit M, Ayuketang F, Triviai I, Zander A, Alchalby H, Bacher U, Fehse B, Kröger N
BONE MARROW TRANSPL. 2017;52(11):1526-1529.

2016

Incidence and risk factors of poor graft function after allogeneic stem cell transplantation for myelofibrosis
Alchalby H, Yunus D, Zabelina T, Ayuketang F, Kröger N
BONE MARROW TRANSPL. 2016;51(9):1223-7.

Digital-PCR assay for screening and quantitative monitoring of calreticulin (CALR) type-2 positive patients with myelofibrosis following allogeneic stem cell transplantation
Badbaran A, Fehse B, Christopeit M, Aranyossy T, Ayuketang F, Wolschke C, Kröger N
BONE MARROW TRANSPL. 2016;51(6):872-3.

Correlation of somatic mutations with outcome after FLAMSA-busulfan sequential conditioning and allogeneic stem cell transplantation in patients with MDS
Christopeit M, Badbaran A, Alawi M, Zabelina T, Zeck G, Wolschke C, Ayuketang F, Kröger N
EUR J HAEMATOL. 2016;97(3):288-96.

Similar outcome of calreticulin type I and calreticulin type II mutations following RIC allogeneic haematopoietic stem cell transplantation for myelofibrosis
Christopeit M, Badbaran A, Zabelina T, Zeck G, Fehse B, Ayuketang F, Wolschke C, Kröger N
BONE MARROW TRANSPL. 2016;51(10):1391-1393.

Serial 18F-FDG PET for Monitoring Treatment Response After Allogeneic Stem Cell Transplantation for Myelofibrosis
Derlin T, Alchalby H, Bannas P, Laqmani A, Ayuketang F, Triviai I, Kreipe H, Bengel F, Kröger N
J NUCL MED. 2016;57(10):1556-1559.

International, Multicenter Standardization of Acute Graft-versus-Host Disease Clinical Data Collection: A Report from the Mount Sinai Acute GVHD International Consortium
Harris A, Young R, Devine S, Hogan W, Ayuketang F, Bunworasate U, Chanswangphuwana C, Efebera Y, Holler E, Litzow M, Ordemann R, Qayed M, Renteria A, Reshef R, Wölfl M, Chen Y, Goldstein S, Jagasia M, Locatelli F, Mielke S, Porter D, Schechter T, Shekhovtsova Z, Ferrara J, Levine J
BIOL BLOOD MARROW TR. 2016;22(1):4-10.

Late acute graft versus host disease: a prospective analysis of clinical outcomes and circulating angiogenic factors
Holtan S, Khera N, Levine J, Chai X, Storer B, Liu H, Inamoto Y, Chen G, Mayer S, Arora M, Palmer J, Flowers M, Cutler C, Lukez A, Arai S, Lazaryan A, Newell L, Krupski C, Jagasia M, Pusic I, Wood W, Renteria A, Yanik G, Hogan W, Hexner E, Ayuketang F, Holler E, Watanaboonyongcharoen P, Efebera Y, Ferrara J, Panoskaltsis-Mortari A, Weisdorf D, Lee S, Pidala J
BLOOD. 2016;128(19):2350-2358.

Antilymphocyte Globulin for Prevention of Chronic Graft-versus-Host Disease
Kröger N, Solano C, Wolschke C, Bandini G, Patriarca F, Pini M, Nagler A, Selleri C, Risitano A, Messina G, Bethge W, Pérez de Oteiza J, Duarte R, Carella A, Cimminiello M, Guidi S, Finke J, Mordini N, Ferra C, Sierra J, Russo D, Petrini M, Milone G, Benedetti F, Heinzelmann M, Pastore D, Jurado M, Terruzzi E, Narni F, Völp A, Ayuketang F, Ruutu T, Bonifazi F
NEW ENGL J MED. 2016;374(1):43-53.

Blood-borne Hepatitis E Virus Transmission: A Relevant Risk for Immunosuppressed Patients
Pischke S, Hiller J, Lütgehetmann M, Polywka S, Rybczynski M, Ayuketang F, Lohse A
CLIN INFECT DIS. 2016;63(4):569-570.

Outcome after Transplantation According to Reduced-Intensity Conditioning Regimen in Patients Undergoing Transplantation for Myelofibrosis
Robin M, Porcher R, Wolschke C, Sicre de Fontbrune F, Alchalby H, Christopeit M, Cassinat B, Zabelina T, Peffault de Latour R, Ayuketang F, Socié G, Kröger N
BIOL BLOOD MARROW TR. 2016;22(7):1206-11.

Potent in vitro and in vivo effects of polyclonal anti-human-myeloma globulins
Schieferdecker A, Shoshani O, Westner B, Zipori D, Fehse B, Kröger N, Ayuketang F
ONCOTARGET. 2016;7(41):67061-67070.

2015

Prognostic factors for survival of patients with newly diagnosed chronic GVHD according to NIH criteria
Ayuketang F, Veit R, Zabelina T, Bussmann L, Christopeit M, Alchalby H, Wolschke C, Lellek H, Bacher U, Zander A, Kröger N
ANN HEMATOL. 2015;94(10):1727-32.

Magnetic resonance enterography for assessment of intestinal graft-versus-host disease after allogeneic stem cell transplantation
Derlin T, Laqmani A, Veldhoen S, Apostolova I, Ayuketang F, Adam G, Kröger N, Bannas P
EUR RADIOL. 2015;25(5):1229-1237.

Allogeneic stem cell transplantation after conditioning with treosulfan, etoposide and cyclophosphamide for patients with ALL: a phase II-study on behalf of the German Cooperative Transplant Study Group and ALL Study Group (GMALL)
Kröger N, Bornhäuser M, Stelljes M, Pichlmeier U, Trenschel R, Schmid C, Arnold R, Martin H, Heinzelmann M, Wolschke C, Meyer R, Bethge W, Kobbe G, Ayuketang F, Gökbuget N, Hölzer D, Zander A, Beelen D
BONE MARROW TRANSPL. 2015;50(12):1503-7.

Atovaquone for Prophylaxis of Toxoplasmosis after Allogeneic Hematopoietic Stem Cell Transplantation.
Mendorf A, Klyuchnikov E, Langebrake C, Rohde H, Ayuketang F, Regier M, Christopeit M, Zabelina T, Bacher A, Stübig T, Wolschke C, Bacher U, Kroger N
ACTA HAEMATOL-BASEL. 2015;134(3):146-154.

Stammzelltransplantation bei Multipler Sklerose. Hamburger Erfahrungen und internationaler Forschungsstand
Stellmann J, Stürner K, Ufer F, Havemeister S, Pöttgen J, Ayuketang F, Kröger N, Friese M, Heesen C
NERVENARZT. 2015;86(8):989-96.

Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey
Zeiser R, Burchert A, Lengerke C, Verbeek M, Maas-Bauer K, Metzelder S, Spoerl S, Ditschkowski M, Ecsedi M, Sockel K, Ayuketang F, Ajib S, de Fontbrune F, Na I, Penter L, Holtick U, Wolf D, Schuler E, Meyer E, Apostolova P, Bertz H, Marks R, Lübbert M, Wäsch R, Scheid C, Stölzel F, Ordemann R, Bug G, Kobbe G, Negrin R, Brune M, Spyridonidis A, Schmitt-Gräff A, van der Velden W, Huls G, Mielke S, Grigoleit G, Kuball J, Flynn R, Ihorst G, Du J, Blazar B, Arnold R, Kröger N, Passweg J, Halter J, Socié G, Beelen D, Peschel C, Neubauer A, Finke J, Duyster J, von Bubnoff N
LEUKEMIA. 2015;29(10):2062-8.

2014

Serum albumin level predicts survival of patients with gastrointestinal acute graft-versus-host disease after allogeneic stem cell transplantation
Ayuketang F, Bussmann L, Zabelina T, Veit R, Alchalby H, Wolschke C, Lellek H, Bacher U, Zander A, Kröger N
ANN HEMATOL. 2014;93(5):855-61.

Postallogeneic monitoring with molecular markers detected by pretransplant next-generation or Sanger sequencing predicts clinical relapse in patients with myelodysplastic/myeloproliferative neoplasms
Fu Y, Schroeder T, Zabelina T, Badbaran A, Bacher U, Kobbe G, Ayuketang F, Wolschke C, Schnittger S, Kohlmann A, Haferlach T, Kröger N
EUR J HAEMATOL. 2014;92(3):189-94.

CD34(+)-selected stem cell boost without further conditioning for poor graft function after allogeneic stem cell transplantation in patients with hematological malignancies
Klyuchnikov E, El-Cheikh J, Sputtek A, Lioznov M, Calmels B, Furst S, Chabannon C, Crocchiolo R, Lemarié C, Faucher C, Bacher U, Alchalby H, Stübig T, Wolschke C, Ayuketang F, Reckhaus M, Blaise D, Kröger N
BIOL BLOOD MARROW TR. 2014;20(3):382-6.

Dynamic of bone marrow fibrosis regression predicts survival after allogeneic stem cell transplantation for myelofibrosis
Kröger N, Zabelina T, Alchalby H, Stübig T, Wolschke C, Ayuketang F, von Huenerbein N, Kvasnicka H, Thiele J, Kreipe H, Büsche G
BIOL BLOOD MARROW TR. 2014;20(6):812-5.

Synergistic cytotoxic activity of treosulfan and gemcitabine in pancreatic cancer cell lines
Nitsch E, Mina S, Brammer I, Pace A, Schuch G, Bokemeyer C, Zander A, Kröger N, Ayuketang F
ANTICANCER RES. 2014;34(4):1779-84.

JAK inhibition with ruxolitinib as pretreatment for allogeneic stem cell transplantation in primary or post-ET/PV myelofibrosis
Stübig T, Alchalby H, Ditschkowski M, Wolf D, Wulf G, Zabelina T, Wolschke C, Ayuketang F, Kröger N
LEUKEMIA. 2014;28(8):1736-8.

Effective prevention of GVHD using in vivo T-cell depletion with anti-lymphocyte globulin in HLA-identical or -mismatched sibling peripheral blood stem cell transplantation
Wolschke C, Zabelina T, Ayuketang F, Alchalby H, Berger J, Klyuchnikov E, Pein U, Schumacher S, Amtsfeld G, Adjallé R, Wortmann F, Lellek H, Randenborgh A, Zander A, Kröger N
BONE MARROW TRANSPL. 2014;49(1):126-30.

2013

Donor choice according to age for allo-SCT for AML in complete remission
Ayuketang F, Zabelina T, Wortmann F, Alchalby H, Wolschke C, Lellek H, Bacher U, Zander A, Kröger N
BONE MARROW TRANSPL. 2013;48(8):1028-32.

Impact of physiological BM CD10+CD19+ B-cell precursors (haematogones) in the post-transplant period in patients with AML
Christopeit M, Heiland A, Binder M, Zabelina T, Ayuketang F, Horn C, Haferlach T, Bokemeyer C, Kröger N, Bacher U
BONE MARROW TRANSPL. 2013;48(9):1257-9.

Evaluation of BM cytomorphology after allo-SCT in patients with MDS
Christopeit M, Ocheni S, Haferlach T, Miersch K, Zabelina T, Klyuchnikov E, Binder M, Ayuketang F, Schafhausen P, Zander A, Bokemeyer C, Kröger N, Bacher U
BONE MARROW TRANSPL. 2013;48(3):465-6.

Impact of high-risk cytogenetics and achievement of molecular remission on long-term freedom from disease after autologous-allogeneic tandem transplantation in patients with multiple myeloma.
Kröger N, Badbaran A, Zabelina T, Ayuketang F, Wolschke C, Alchalby H, Klyuchnikov E, Atanackovic D, Schilling G, Hansen T, Schwarz S, Heinzelmann M, Zeschke S, Bacher U, Stübig T, Fehse B, Zander A
BIOL BLOOD MARROW TR. 2013;19(3):398-404.

Toxicity-reduced, myeloablative allograft followed by lenalidomide maintenance as salvage therapy for refractory/relapsed myeloma patients.
Kröger N, Zabelina T, Klyuchnikov E, Kropff M, Pflüger K, Burchert A, Stübig T, Wolschke C, Ayuketang F, Hildebrandt Y, Bacher U, Badbaran A, Schilling G, Hansen T, Atanackovic D, Zander A
BONE MARROW TRANSPL. 2013;48(3):403-407.

Rapid activation of monocyte tissue factor by antithymocyte globulin is dependent on complement and protein disulfide isomerase
Langer F, Spath B, Fischer C, Stolz M, Ayuketang F, Kröger N, Bokemeyer C, Ruf W
BLOOD. 2013;121(12):2324-35.

Outcome of allogeneic SCT in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy.
Oyekunle A, Zander A, Binder M, Ayuketang F, Zabelina T, Christopeit M, Stübig T, Alchalby H, Schafhausen P, Lellek H, Wolschke C, Müller I, Bacher U, Kröger N
ANN HEMATOL. 2013;92(4):487-496.

Postallograft lenalidomide induces strong NK cell-mediated antimyeloma activity and risk for T cell-mediated GvHD: Results from a phase I/II dose-finding study.
Wolschke C, Stübig T, Hegenbart U, Schönland S, Heinzelmann M, Hildebrandt Y, Ayuketang Ayuk F, Atanackovic D, Dreger P, Zander A, Kröger N
EXP HEMATOL. 2013;41(2):133-134.

2012

Risk models predicting survival after reduced-intensity transplantation for myelofibrosis.
Alchalby H, Yunus D, Zabelina T, Kobbe G, Holler E, Bornhäuser M, Schwerdtfeger R, Bethge W, Kvasnicka H, Büsche G, Ayuketang Ayuk F, Bacher U, Zander A, Kröger N
BRIT J HAEMATOL. 2012;157(1):75-85.

Evaluation of BM cytomorphology after allo-SCT in patients with AML
Christopeit M, Miersch K, Klyuchnikov E, Haferlach T, Binder M, Zabelina T, Ayuketang Ayuk F, Schafhausen P, Zander A, Bokemeyer C, Kröger N, Bacher U
BONE MARROW TRANSPL. 2012;47(12):1538-1544.

2011

Circulating CD34(+) cells as prognostic and follow-up marker in patients with myelofibrosis undergoing allo-SCT.
Alchalby H, Lioznov M, Fritzsche-Friedland U, Badbaran A, Zabelina T, Bacher U, Stübig T, Ayuketang Ayuk F, Zander A, Kröger N
BONE MARROW TRANSPL. 2011;47(1):143-145.

The Role of Allogeneic Stem Cell Transplantation in Relapsed/Refractory Hodgkin's Lymphoma Patients.
Klyuchnikov E, Bacher U, Kröger N, Kazantsev I, Zabelina T, Ayuketang Ayuk F, Zander A
ANN HEMATOL. 2011;2011:974658.

Purification of CD4+ T cells for adoptive immunotherapy after allogeneic hematopoietic stem cell transplantation
Klyuchnikov E, Sputtek A, Slesarchuk O, Lioznov M, Stübig T, Bacher U, Amtsfeld G, Merle E, Reckhaus M, Fehse B, Wolschke C, Adjalle R, Ayuketang Ayuk F, Zander A, Kröger N
BIOL BLOOD MARROW TR. 2011;17(3):374-383.

Donor KIR haplotype B improves progression-free and overall survival after allogeneic hematopoietic stem cell transplantation for multiple myeloma.
Kröger N, Zabelina T, Berger J, Duske H, Klyuchnikov E, Binder T, Stübig T, Hildebrandt Y, Atanackovic D, Alchalby H, Ayuketang Ayuk F, Zander A, Bacher U, Eiermann T
LEUKEMIA. 2011;25(10):1657-1661.

Caspofungin plus posaconazole as salvage therapy of invasive fungal infections in immunocompromised patients.
Lellek H, Waldenmaier D, Dahlke J, Ayuketang Ayuk F, Wolschke C, Kröger N, Zander A
MYCOSES. 2011;54(1):39-44.

Consensus Conference on Clinical Practice in Chronic GVHD: Second-Line Treatment of Chronic Graft-versus-Host Disease.
Wolff D, Schleuning M, von Harsdorf S, Bacher U, Gerbitz A, Stadler M, Ayuketang Ayuk F, Kiani A, Schwerdtfeger R, Vogelsang G, Kobbe G, Gramatzki M, Lawitschka A, Mohty M, Pavletic S, Greinix H, Holler E
BIOL BLOOD MARROW TR. 2011;17(1):1-17.

2010

Diagnosis of Toxoplasma gondii infection after allogeneic stem cell transplant can be difficult and requires intensive scrutiny.
Cavattoni I, Ayuketang Ayuk F, Zander A, Zabelina T, Bacher A, Cayiroglu E, Knospe V, Illies T, Aepfelbacher M, Richard G, Kröger N, Bacher U
LEUKEMIA LYMPHOMA. 2010;51(8):1530-1535.

Pilot study of rituximab plus donor-lymphocyte infusion to prevent or treat relapse in B-cell lymphoma after allogeneic stem cell transplantation.
Cavattoni I, Zabelina T, Ayuketang Ayuk F, Wolschke C, Bacher U, Zander A, Kröger N
LEUKEMIA LYMPHOMA. 2010;51(1):146-148.

Immunohistochemistry and molecular analyses in myeloid sarcoma of the breast in a patient with relapse of NPM1-mutated and FLT3-mutated AML after allogeneic stem cell transplantation.
Choschzick M, Bacher U, Ayuketang Ayuk F, Lebeau A
J CLIN PATHOL. 2010;63(6):558-561.

Post-transplant immune reconstitution after unrelated allogeneic stem cell transplant in patients with acute myeloid leukemia.
Klyuchnikov E, Asenova S, Kern W, Kilinc G, Ayuketang Ayuk F, Wiedemann B, Lioznov M, Freiberger P, Zalyalov Y, Zander A, Kröger N, Bacher U
LEUKEMIA LYMPHOMA. 2010;51(8):1450-1463.

Influence of mannose-binding lectin genotypes and serostatus in allo-SCT: analysis of 131 recipients and donors.
Neth O, Bacher U, Das P, Zabelina T, Kabisch H, Kroeger N, Ayuketang F, Lioznov M, Waschke O, Fehse B, Thiébaut R, Haston R, Klein N, Zander A
BONE MARROW TRANSPL. 2010;45(1):13-9.

Second Allogeneic Stem Cell Transplantation in a Patient with Hypoplastic Myelodysplastic Syndrome following a Primary Diagnosis of Aplastic Anaemia.
Ocheni S, Oyekunle A, Kröger N, Ayuketang Ayuk F, Klyuchnikov E, Arps S, Held K, Zabelina T, Adjalle R, Wolschke C, Zander A, Bacher U
ACTA HAEMATOL-BASEL. 2010;125(3):175-178.

Allogenic hematopoietic stem-cell transplantation with reduced-intensity conditioning in patients with refractory and recurrent multiple myeloma: long-term follow-up.
Shimoni A, Hardan I, Ayuketang Ayuk F, Schilling G, Atanackovic D, Zeller W, Yerushalmi R, Zander A, Kröger N, Nagler A
CANCER-AM CANCER SOC. 2010;116(15):3621-3630.

Minimal residual disease diagnostics in patients with acute myeloid leukemia in the post-transplant period: comparison of peripheral blood and bone marrow analysis.
Stahl T, Badbaran A, Kröger N, Klyuchnikov E, Zabelina T, Zeschke S, Schafhausen P, Schultz W, Asenova S, Smirnova A, Wolschke C, Ayuketang Ayuk F, Zander A, Fehse B, Bacher U
LEUKEMIA LYMPHOMA. 2010;51(10):1837-1843.

Chimerism studies with quantitative real-time PCR in stem cell recipients with acute myeloid leukemia.
Wiedemann B, Klyuchnikov E, Kröger N, Zabelina T, Stahl T, Zeschke S, Badbaran A, Ayuketang Ayuk F, Alchalby H, Wolschke C, Bokemeyer C, Fehse B, Zander A, Bacher U
EXP HEMATOL. 2010;38(12):1261-1271.

Consensus conference on clinical practice in chronic graft-versus-host disease (GVHD): first-line and topical treatment of chronic GVHD.
Wolff D, Gerbitz A, Ayuketang Ayuk F, Kiani A, Hildebrandt G, Vogelsang G, Elad S, Lawitschka A, Socie G, Pavletic S, Holler E, Greinix H
BIOL BLOOD MARROW TR. 2010;16(12):1611-1628.

2009

Comparison of the cytotoxicity of 4 preparations of anti-T-cell globulins in various hematological malignancies.
Ayuketang Ayuk F, Maywald N, Hannemann S, Larsen U, Zander A, Kröger N
ANTICANCER RES. 2009;29(4):1355-1360.

Antitumor effects of polyclonal antithymocyte globulins: focus on B-cell malignancies and multiple myeloma.
Ayuketang Ayuk F, Zander A, Kröger N
ANN HEMATOL. 2009;88(5):401-404.

Bone marrow mesenchymal stromal cells remain of recipient origin after allogeneic SCT and do not harbor the JAK2V617F mutation in patients with myelofibrosis.
Bacher U, Asenova S, Badbaran A, Zander A, Alchalby H, Fehse B, Kröger N, Lange C, Ayuketang Ayuk F
CLIN EXP MED. 2009.

Second allogeneic stem cell transplantation in myeloid malignancies.
Hartwig M, Ocheni S, Asenova S, Wiedemann B, Zabelina T, Ayuketang Ayuk F, Kabisch H, Erttmann R, Kröger N, Zander A, Bacher U
ACTA HAEMATOL-BASEL. 2009;122(4):185-192.

Second-generation tyrosine kinase inhibitors in the post-transplant period in patients with chronic myeloid leukemia or Philadelphia-positive acute lymphoblastic leukemia.
Klyuchnikov E, Schafhausen P, Kröger N, Brümmendorf T, Osanmaz O, Asenova S, Zabelina T, Ocheni S, Ayuketang Ayuk F, Zander A, Bacher U
ACTA HAEMATOL-BASEL. 2009;122(1):6-10.

JAK2-V617F-triggered preemptive and salvage adoptive immunotherapy with donor-lymphocyte infusion in patients with myelofibrosis after allogeneic stem cell transplantation.
Kröger N, Alchalby H, Klyuchnikov E, Badbaran A, Hildebrandt Y, Ayuketang Ayuk F, Bacher U, Bock O, Kvasnicka M, Fehse B, Zander A
BLOOD. 2009;113(8):1866-1868.

Post-transplant immunotherapy with donor-lymphocyte infusion and novel agents to upgrade partial into complete and molecular remission in allografted patients with multiple myeloma.
Kröger N, Badbaran A, Lioznov M, Schwartz S, Zeschke S, Hildebrandt Y, Ayuketang Ayuk F, Atanackovic D, Schilling G, Zabelina T, Bacher U, Klyuchnikov E, Shimoni A, Nagler A, Corradini P, Fehse B, Zander A
EXP HEMATOL. 2009;37(7):791-798.

HLA-mismatched unrelated donors as an alternative graft source for allogeneic stem cell transplantation after antithymocyte globulin-containing conditioning regimen.
Kröger N, Zabelina T, Binder T, Ayuketang Ayuk F, Bacher U, Amtsfeld G, Lellek H, Schrum J, Erttmann R, Eiermann T, Zander A
BIOL BLOOD MARROW TR. 2009;15(4):454-462.

Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44(+)) and T (HLA-DR(+)) cells.
Lioznov M, El-Cheikh J, Hoffmann F, Hildebrandt Y, Ayuketang Ayuk F, Wolschke C, Atanackovic D, Schilling G, Badbaran A, Bacher U, Fehse B, Zander A, Blaise D, Mohty M, Kröger N
BONE MARROW TRANSPL. 2009.

Characterisation of extramedullary relapse in patients with chronic myeloid leukemia in advanced disease after allogeneic stem cell transplantation.
Ocheni S, Iwanski G, Schafhausen P, Zander A, Ayuketang Ayuk F, Klyuchnikov E, Zabelina T, Fiedler W, Schnittger S, Hochhaus A, Brümmendorf T, Kröger N, Bacher U
LEUKEMIA LYMPHOMA. 2009;50(4):551-558.

Pegfilgrastim compared to lenograstim after allogeneic peripheral blood stem-cell transplantation from unrelated donors.
Ocheni S, Zabelina T, Bacher U, Ayuketang Ayuk F, Zander A, Kröger N
LEUKEMIA LYMPHOMA. 2009;50(4):612-618.

2008

Complement-dependent and complement-independent cytotoxicity of polyclonal antithymocyte globulins in chronic lymphocytic leukemia.
Ayuketang Ayuk F, Atassi N, Schuch G, Mina S, Fang L, Bokemeyer C, Fehse B, Zander A, Kröger N
LEUKEMIA RES. 2008;32(8):1200-1206.

Anti-thymocyte globulin overcomes the negative impact of HLA mismatching in transplantation from unrelated donors.
Ayuketang Ayuk F, Diyachenko G, Zabelina T, Panse J, Wolschke C, Eiermann T, Binder T, Fehse B, Erttmann R, Kabisch H, Bacher U, Kröger N, Zander A
EXP HEMATOL. 2008;36(8):1047-1054.

Comparison of two doses of antithymocyte globulin in patients undergoing matched unrelated donor allogeneic stem cell transplantation.
Ayuketang Ayuk F, Diyachenko G, Zabelina T, Wolschke C, Fehse B, Bacher U, Erttmann R, Kröger N, Zander A
BIOL BLOOD MARROW TR. 2008;14(8):913-919.

Clinical impact of human Jurkat T-cell-line-derived antithymocyte globulin in multiple myeloma patients undergoing allogeneic stem cell transplantation.
Ayuketang Ayuk F, Perez-Simon J, Shimoni A, Sureda A, Zabelina T, Schwerdtfeger R, Martino R, Sayer H, Alegre A, Lahuerta J, Atanackovic D, Wolschke C, Nagler A, Zander A, Miguel S, Kröger N, Kröger N
HAEMATOLOGICA. 2008;93(9):1343-1350.

EBV reactivation and post transplant lymphoproliferative disorders following allogeneic SCT.
Ocheni S, Kröger N, Zabelina T, Sobottka I, Ayuketang Ayuk F, Wolschke C, Muth A, Lellek H, Petersen L, Erttmann R, Kabisch H, Zander A, Bacher U
BONE MARROW TRANSPL. 2008;42(3):181-186.

Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma.
Schilling G, Hansen T, Shimoni A, Zabelina T, Pérez-Simón J, Simon-Perez J, Gutierrez N, Fiedler W, Liebisch P, Schwerdtfeger R, Bornhäuser M, Otterstetter S, Murga-Penas E, Dierlamm J, Ayuketang Ayuk F, Atanackovic D, Bacher U, Bokemeyer C, Zander A, San Miguel J, Miguel J, Nagler A, Kröger N
LEUKEMIA. 2008;22(6):1250-1255.

2007

Monitoring serum free light chains in patients with multiple myeloma who achieved negative immunofixation after allogeneic stem cell transplantation.
Mösbauer U, Ayuketang Ayuk F, Schieder H, Lioznov M, Zander A, Kröger N
HAEMATOLOGICA. 2007;92(2):275-276.

2006

Comparable results in patients with acute lymphoblastic leukemia after related and unrelated stem cell transplantation.
Dahlke J, Kröger N, Zabelina T, Ayuketang Ayuk F, Wolschke C, Renges H, Krüger W, Kruell A, Hinke A, Erttmann R, Kabisch H, Zander A
BONE MARROW TRANSPL. 2006;37(2):155-163.

Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma.
Donk v, Kröger N, Kröger N, Hegenbart U, Corradini P, Miguel S, Jesus F, Goldschmidt H, Perez-Simon J, Zijlmans M, Ayuketang Ayuk F, Montefusco V, Ayuk F, Oers v, Marinus H, Nagler A, Verdonck L, Lokhorst H
BLOOD. 2006;107(8):3415-3416.

Low number of donor activating killer immunoglobulin-like receptors (KIR) genes but not KIR-ligand mismatch prevents relapse and improves disease-free survival in leukemia patients after in vivo T-cell depleted unrelated stem cell transplantation.
Kröger N, Binder T, Zabelina T, Wolschke C, Schieder H, Renges H, Ayuketang Ayuk F, Dahlke J, Eiermann T, Zander A
TRANSPLANTATION. 2006;82(8):1024-1030.

Reduced-toxicity conditioning with treosulfan, fludarabine and ATG as preparative regimen for allogeneic stem cell transplantation (alloSCT) in elderly patients with secondary acute myeloid leukemia (sAML) or myelodysplastic syndrome (MDS).
Kröger N, Shimoni A, Zabelina T, Schieder H, Panse J, Ayuketang Ayuk F, Wolschke C, Renges H, Dahlke J, Atanackovic D, Nagler A, Zander A
BONE MARROW TRANSPL. 2006;37(4):339-344.

Bortezomib after dose-reduced allogeneic stem cell transplantation for multiple myeloma to enhance or maintain remission status.
Kröger N, Zabelina T, Ayuketang Ayuk F, Atanackovic D, Schieder H, Renges H, Zander A
EXP HEMATOL. 2006;34(6):770-775.

Kinetics of plasma-cell chimerism after allogeneic stem cell transplantation by highly sensitive real-time PCR based on sequence polymorphism and its value to quantify minimal residual disease in patients with multiple myeloma.
Kröger N, Zagrivnaja M, Schwartz S, Badbaran A, Zabelina T, Lioznov M, Ayuketang Ayuk F, Zander A, Fehse B
EXP HEMATOL. 2006;34(5):688-694.

CD34(+)-selected stem cell boost for delayed or insufficient engraftment after allogeneic stem cell transplantation.
Oyekunle A, Koehl U, Schieder H, Ayuketang Ayuk F, Renges H, Fehse N, Zabelina T, Fehse B, Klingebiel T, Sputtek A, Zander A, Kröger N
CYTOTHERAPY. 2006;8(4):375-380.

Allogeneic stem-cell transplantation in patients with refractory acute leukemia: a long-term follow-up.
Oyekunle A, Kröger N, Zabelina T, Ayuketang Ayuk F, Schieder H, Renges H, Fehse N, Waschke O, Fehse B, Kabisch H, Zander A
BONE MARROW TRANSPL. 2006;37(1):45-50.

Prognostic factors for donor lymphocyte infusions following non-myeloablative allogeneic stem cell transplantation in multiple myeloma.
van de Donk N, Kröger N, Hegenbart U, Corradini P, San Miguel J, Goldschmidt H, Perez-Simon J, Zijlmans M, Raymakers R, Montefusco V, Ayuketang Ayuk F, van Oers M, Nagler A, Verdonck L, Lokhorst H
BONE MARROW TRANSPL. 2006;37(12):1135-1141.

2005

Antithymocyte globulin induces complement-dependent cell lysis and caspase-dependent apoptosis in myeloma cells.
Ayuketang Ayuk F, Fang L, Fehse B, Zander A, Kröger N
EXP HEMATOL. 2005;33(12):1531-1536.

Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR-ligand mismatch after dose-reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma.
Kröger N, Shaw B, Iacobelli S, Zabelina T, Peggs K, Shimoni A, Nagler A, Binder T, Eiermann T, Madrigal A, Schwerdtfeger R, Kiehl M, Sayer H, Beyer J, Bornhäuser M, Ayuketang Ayuk F, Zander A, Marks D
BRIT J HAEMATOL. 2005;129(5):631-643.

Hematopoietic stem-cell transplantation from unrelated donors in elderly patients (age >55 years) with hematologic malignancies: older age is no longer a contraindication when using reduced intensity conditioning.
Shimoni A, Kröger N, Zabelina T, Ayuketang Ayuk F, Hardan I, Yeshurun M, Shem-Tov N, Avigdor A, Ben-Bassat I, Zander A, Nagler A
LEUKEMIA. 2005;19(1):7-12.

2004

Efficacy and toxicity of low-dose escalating donor lymphocyte infusion given after reduced intensity conditioning allograft for multiple myeloma.
Ayuketang Ayuk F, Shimoni A, Nagler A, Schwerdtfeger R, Kiehl M, Sayer H, Zabelina T, Zander A, Kröger N
LEUKEMIA. 2004;18(3):659-662.

Evidence for increased risk of secondary graft failure after in vivo depletion of suicide gene-modified T lymphocytes transplanted in conjunction with CD34+-enriched blood stem cells.
Fehse B, Ayuketang Ayuk F, Kröger N, Fang L, Kühlcke K, Heinzelmann M, Zabelina T, Fauser A, Zander A
BLOOD. 2004;104(10):3408-3409.

Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma.
Kröger N, Perez-Simon J, Myint H, Klingemann H, Shimoni A, Nagler A, Martino R, Alegre A, Tomas J, Schwerdtfeger R, Kiehl M, Fauser A, Sayer H, Leon A, Beyer J, Zabelina T, Ayuketang Ayuk F, Miguel S, Jesus F, Brand R, Zander A
BIOL BLOOD MARROW TR. 2004;10(10):698-708.

Low-dose thalidomide and donor lymphocyte infusion as adoptive immunotherapy after allogeneic stem cell transplantation in patients with multiple myeloma.
Kröger N, Shimoni A, Zagrivnaja M, Ayuketang Ayuk F, Lioznov M, Schieder H, Renges H, Fehse B, Zabelina T, Nagler A, Zander A
BLOOD. 2004;104(10):3361-3363.

2003

Myeloablative intensified conditioning regimen with in vivo T-cell depletion (ATG) followed by allografting in patients with advanced multiple myeloma. A phase I/II study of the German Study-group Multiple Myeloma (DSMM).
Kröger N, Einsele H, Wolff D, Casper J, Freund M, Derigs G, Wandt H, Schäfer-Eckart K, Wittkowsky G, Schmitz N, Krüger W, Zabelina T, Renges H, Ayuketang Ayuk F, Krüll A, Zander A
BONE MARROW TRANSPL. 2003;31(11):973-979.

2002

Dose-reduced conditioning regimen followed by allogeneic stem cell transplantation in patients with myelofibrosis with myeloid metaplasia.
Hessling J, Kröger N, Werner M, Zabelina T, Hansen A, Kordes U, Ayuketang Ayuk F, Renges H, Panse J, Erttmann R, Zander A
BRIT J HAEMATOL. 2002;119(3):769-772.

Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality.
Kröger N, Sayer H, Schwerdtfeger R, Kiehl M, Nagler A, Renges H, Zabelina T, Fehse B, Ayuketang Ayuk F, Wittkowsky G, Schmitz N, Zander A
BLOOD. 2002;100(12):3919-3924.

In vivo T cell depletion with pretransplant anti-thymocyte globulin reduces graft-versus-host disease without increasing relapse in good risk myeloid leukemia patients after stem cell transplantation from matched related donors.
Kröger N, Zabelina T, Krüger W, Renges H, Stute N, Rischewski J, Sonnenberg S, Ayuk F, Ayuketang Ayuk F, Schade U, Fiegel H, Erttmann R, Löliger C, Zander A
BONE MARROW TRANSPL. 2002;29(8):683-689.

Long-term follow-up of allogeneic stem cell transplantation in patients with severe aplastic anemia after conditioning with cyclophosphamide plus antithymocyte globulin.
Kröger N, Zabelina T, Renges H, Krüger W, Kordes U, Rischewski J, Schrum J, Horstmann M, Ayuketang Ayuk F, Erttmann R, Kabisch H, Zander A
ANN HEMATOL. 2002;81(11):627-631.

Highly efficient retroviral gene transfer based on centrifugation-mediated vector preloading of tissue culture vessels.
Kühlcke K, Fehse B, Schilz A, Loges S, Lindemann C, Ayuketang Ayuk F, Lehmann F, Stute N, Fauser A, Zander A, Eckert H
MOL THER. 2002;5(4):473-478.

2001

T lymphocytes as targets of gene transfer with Moloney-type retroviral vectors.
Ayuketang Ayuk F, Zander A, Fehse B
CURR GENE THER. 2001;1(4):325-337.

2000

Retroviral transduction of T lymphocytes for suicide gene therapy in allogeneic stem cell transplantation.
Kühlcke K, Ayuketang Ayuk F, Li Z, Lindemann C, Schilz A, Schade U M, Fauser A, Zander A, Eckert H, Fehse B
BONE MARROW TRANSPL. 2000;25(2):96-98.

1999

Establishment of an optimised gene transfer protocol for human primary T lymphocytes according to clinical requirements.
Ayuketang Ayuk F, Li Z, Kühlcke K, Lindemann C, Schade U, Eckert H, Zander A, Fehse B
GENE THER. 1999;6(10):1788-1792.

Letzte Aktualisierung aus dem FIS: 23.12.2024 - 23:35 Uhr